Generic placeholder image

Anti-Cancer Agents in Medicinal Chemistry

Editor-in-Chief

ISSN (Print): 1871-5206
ISSN (Online): 1875-5992

Review Article

Role of KSP Inhibitors as Anti-Cancer Therapeutics: An Update

Author(s): Rinkal Chamariya and Vasanti Suvarna*

Volume 22, Issue 14, 2022

Published on: 18 April, 2022

Page: [2517 - 2538] Pages: 22

DOI: 10.2174/1871520622666220119093105

Price: $65

Abstract

Regardless of the growing discovery of anticancer treatments targeting cancer-specific pathways, cytotoxic therapy still maintained its abundant clinical significance because tumours harbor a greater population of actively dividing cells than normal tissues. Conventional anti-mitotic agents or microtubule poisons acting on the major mitotic spindle protein tubulin have been effectively used in clinical settings for cancer chemotherapy over the last three decades. However, the use of these drugs is associated with limited clinical utility due to serious side effects such as debilitating and dose-limiting peripheral neuropathy, myelosuppression, drug resistance, and allergic reactions. Therefore, research initiatives have been undertaken to develop novel microtubule motor proteins inhibitors that can potentially circumvent the limitations associated with conventional microtubule poisons. Kinesin spindle proteins (KSP) belonging to the kinesin-5 family play a crucial role during mitosis and unregulated cell proliferation. Evidence from preclinical studies and different phases of clinical trials have presented kinesin spindle protein as a promising target for cancer therapeutics. Kinesin spindle protein inhibitors causing mitosis disruption without interfering with microtubule dynamics in non-dividing cells offer a potential therapeutic alternative for the management of several major cancer types and are devoid of side effects associated with classical anti-mitotic drugs. This review summarizes recent data highlighting progress in the discovery of targeted KSP inhibitors and presents the development of scaffolds, structure-activity relationships, and outcomes of biological and enzyme inhibition studies. We reviewed the recent literature reports published over the last decade, using various electronic database searches such as PubMed, Embase, Medline, Web of Science, and Google Scholar. Clinical trial data till 2021 was retrieved from ClinicalTrial.gov. Major chemical classes developed as selective KSP inhibitors include dihydropyrimidines, β-carbolines, carbazoles, benzimidazoles, fused aryl derivatives, pyrimidines, fused pyrimidines, quinazolines, quinolones, thiadiazolines, spiropyran, and azobenzenes. Drugs such as filanesib, litronesib, ispinesib have entered clinical trials; the most advanced phase explored is Phase II. KSP inhibitors have exhibited promising results; however, continued exploration is greatly required to establish the clinical potential of KSP inhibitors.

Keywords: KSP, anti-cancer, Eg5, anti-mitotic, filanesib, dihydropyrimidine.

Graphical Abstract

[1]
Wood, K.W.; Cornwell, W.D.; Jackson, J.R. Past and future of the mitotic spindle as an oncology target. Curr. Opin. Pharmacol., 2001, 1(4), 370-377.
[http://dx.doi.org/10.1016/S1471-4892(01)00064-9] [PMID: 11710735]
[2]
Gascoigne, K.E.; Taylor, S.S. How do anti-mitotic drugs kill cancer cells? J. Cell Sci., 2009, 122(Pt 15), 2579-2585.
[http://dx.doi.org/10.1242/jcs.039719] [PMID: 19625502]
[3]
Waitzman, J.S.; Rice, S.E. Mechanism and regulation of kinesin-5, an essential motor for the mitotic spindle. Biol. Cell, 2014, 106(1), 1-12.
[http://dx.doi.org/10.1111/boc.201300054] [PMID: 24125467]
[4]
Rao, C.V.; Kurkjian, C.D.; Yamada, H.Y. Mitosis-targeting natural products for cancer prevention and therapy. Curr. Drug Targets, 2012, 13(14), 1820-1830.
[http://dx.doi.org/10.2174/138945012804545533] [PMID: 23140292]
[5]
Hirokawa, N.; Mathieu, M.; Rossant, J. Kinesin and dynein superfamily proteins and the mechanism of organelle transport. Science, 1998, 279(5350), 519-526.
[http://dx.doi.org/10.1126/science.279.5350.519] [PMID: 9438838]
[6]
Endow, S.A. Microtubule motors in spindle and chromosome motility. Eur. J. Biochem., 1999, 262(1), 12-18.
[http://dx.doi.org/10.1046/j.1432-1327.1999.00339.x] [PMID: 10231358]
[7]
Wittmann, T.; Hyman, A.; Desai, A. The spindle: a dynamic assembly of microtubules and motors. Nat. Cell Biol., 2001, 3(1), E28-E34.
[http://dx.doi.org/10.1038/35050669] [PMID: 11146647]
[8]
Mandelkow, E.; Mandelkow, E.M. Kinesin motors and disease. Trends Cell Biol., 2002, 12(12), 585-591.
[http://dx.doi.org/10.1016/S0962-8924(02)02400-5] [PMID: 12495847]
[9]
Wordeman, L. The Kinesin Superfamily. In: Cytoskeleton and Human Disease; Kavallaris, M., Ed.; Humana Press: Totowa, 2012; pp. 55-72.
[http://dx.doi.org/10.1007/978-1-61779-788-0_3]
[10]
Rath, O.; Kozielski, F. Kinesins and cancer. Nat. Rev. Cancer, 2012, 12(8), 527-539.
[http://dx.doi.org/10.1038/nrc3310] [PMID: 22825217]
[11]
Rassier, D. Motors: Myosin, kinesin & dynein; Encycl; Biophys, 2013.
[12]
Miki, H.; Okada, Y.; Hirokawa, N. Analysis of the kinesin superfamily: insights into structure and function. Trends Cell Biol., 2005, 15(9), 467-476.
[http://dx.doi.org/10.1016/j.tcb.2005.07.006] [PMID: 16084724]
[13]
Kalchishkova, N.; Böhm, K.J. The role of Kinesin neck linker and neck in velocity regulation. J. Mol. Biol., 2008, 382(1), 127-135.
[http://dx.doi.org/10.1016/j.jmb.2008.06.092] [PMID: 18640125]
[14]
Nyamaa, B.; Kim, H.K.; Jeong, Y.J.; Song, I-S.; Han, J. Kinesin spindle protein inhibition in translational research. J. Lipid Atheroscler., 2014, 3(2), 63-78.
[http://dx.doi.org/10.12997/jla.2014.3.2.63]
[15]
Duan, Y.; Huo, D.; Gao, J.; Wu, H.; Ye, Z.; Liu, Z.; Zhang, K.; Shan, L.; Zhou, X.; Wang, Y.; Su, D.; Ding, X.; Shi, L.; Wang, Y.; Shang, Y.; Xuan, C. Ubiquitin ligase RNF20/40 facilitates spindle assembly and promotes breast carcinogenesis through stabilizing motor protein Eg5. Nat. Commun., 2016, 7(1), 12648.
[http://dx.doi.org/10.1038/ncomms12648] [PMID: 27557628]
[16]
Wissing, M.D.; De Morrée, E.S.; Dezentjé, V.O.; Buijs, J.T.; De Krijger, R.R.; Smit, V.T.; Van Weerden, W.M.; Gelderblom, H.; van der Pluijm, G. Nuclear Eg5 (kinesin spindle protein) expression predicts docetaxel response and prostate cancer aggressiveness. Oncotarget, 2014, 5(17), 7357-7367.
[http://dx.doi.org/10.18632/oncotarget.1985] [PMID: 25277178]
[17]
Sun, L.; Lu, J.; Niu, Z.; Ding, K.; Bi, D.; Liu, S.; Li, J.; Wu, F.; Zhang, H.; Zhao, Z.; Ding, S. A potent chemotherapeutic strategy with Eg5 inhibitor against gemcitabine resistant bladder cancer. PLoS One, 2015, 10(12), e0144484.
[http://dx.doi.org/10.1371/journal.pone.0144484] [PMID: 26658059]
[18]
Ding, S.; Zhao, Z.; Sun, D.; Wu, F.; Bi, D.; Lu, J.; Xing, N.; Sun, L.; Wu, H.; Ding, K. Eg5 inhibitor, a novel potent targeted therapy, induc-es cell apoptosis in renal cell carcinoma. Tumour Biol., 2014, 35(8), 7659-7668.
[http://dx.doi.org/10.1007/s13277-014-2022-x] [PMID: 24801905]
[19]
Lu, M.; Zhu, H.; Wang, X.; Zhang, D.; Xiong, L.; Xu, L.; You, Y. The prognostic role of Eg5 expression in laryngeal squamous cell carci-noma. Pathology, 2016, 48(3), 214-218.
[http://dx.doi.org/10.1016/j.pathol.2016.02.008] [PMID: 27020495]
[20]
Liu, L.; Liu, X.; Mare, M.; Dumont, A.S.; Zhang, H.; Yan, D.; Xiong, Z. Overexpression of Eg5 correlates with high grade astrocytic neo-plasm. J. Neurooncol., 2016, 126(1), 77-80.
[http://dx.doi.org/10.1007/s11060-015-1954-3] [PMID: 26456023]
[21]
Sarli, V.; Giannis, A. Targeting the kinesin spindle protein: basic principles and clinical implications. Clin. Cancer Res., 2008, 14(23), 7583-7587.
[http://dx.doi.org/10.1158/1078-0432.CCR-08-0120] [PMID: 19047082]
[22]
Jackson, J.R.; Patrick, D.R.; Dar, M.M.; Huang, P.S. Targeted anti-mitotic therapies: can we improve on tubulin agents? Nat. Rev. Cancer, 2007, 7(2), 107-117.
[http://dx.doi.org/10.1038/nrc2049] [PMID: 17251917]
[23]
Mayer, T.U.; Kapoor, T.M.; Haggarty, S.J.; King, R.W.; Schreiber, S.L.; Mitchison, T.J. Small molecule inhibitor of mitotic spindle bipolar-ity identified in a phenotype-based screen. Science, 1999, 286(5441), 971-974.
[http://dx.doi.org/10.1126/science.286.5441.971] [PMID: 10542155]
[24]
Maliga, Z.; Kapoor, T.M.; Mitchison, T.J. Evidence that monastrol is an allosteric inhibitor of the mitotic kinesin Eg5. Chem. Biol., 2002, 9(9), 989-996.
[http://dx.doi.org/10.1016/S1074-5521(02)00212-0] [PMID: 12323373]
[25]
Russowsky, D.; Canto, R.F.; Sanches, S.A.; D’Oca, M.G.; de Fátima, A.; Pilli, R.A.; Kohn, L.K.; Antônio, M.A.; de Carvalho, J.E. Synthe-sis and differential antiproliferative activity of Biginelli compounds against cancer cell lines: Monastrol, oxo-monastrol and oxygenated analogues. Bioorg. Chem., 2006, 34(4), 173-182.
[http://dx.doi.org/10.1016/j.bioorg.2006.04.003] [PMID: 16765411]
[26]
Hassan, S.F.; Rashid, U.; Ansari, F.L.; Ul-Haq, Z. Bioisosteric approach in designing new monastrol derivatives: an investigation on their ADMET prediction using in silico derived parameters. J. Mol. Graph. Model., 2013, 45, 202-210.
[http://dx.doi.org/10.1016/j.jmgm.2013.09.002] [PMID: 24080467]
[27]
Gonçalves, I.L.; Rockenbach, L. das Neves, G.M.; Göethel, G.; Nascimento, F.; Porto Kagami, L.; Figueiró, F.; Oliveira de Azambuja, G.; de Fraga Dias, A.; Amaro, A.; de Souza, L.M.; da Rocha Pitta, I.; Avila, D.S.; Kawano, D.F.; Garcia, S.C.; Battastini, A.M.O.; Eifler-Lima, V.L. Effect of N-1 arylation of monastrol on kinesin Eg5 inhibition in glioma cell lines. Med. Chem. Comm., 2018, 9(6), 995-1010.
[http://dx.doi.org/10.1039/C8MD00095F] [PMID: 30108989]
[28]
Gonçalves, I.L.; Rockenbach, L.; Göethel, G.; Saüer, E.; Kagami, L.P. das Neves, G.M.; Munhoz, T.; Figueiró, F.; Garcia, S.C.; Oliveira Battastini, A.M.; Eifler-Lima, V.L. New pharmacological findings linked to biphenyl DHPMs, kinesin Eg5 ligands: anticancer and antioxi-dant effects. Future Med. Chem., 2020, 12(12), 1137-1154.
[http://dx.doi.org/10.4155/fmc-2019-0256] [PMID: 32513026]
[29]
De Oliveira, F.S.; De Oliveira, P.M.; Farias, L.M.; Brinkerhoff, R.C.; Sobrinho, R.C.M.A.; Treptow, T.M.; Montes D’Oca, C.R.; Marinho, M.A.G.; Hort, M.A.; Horn, A.P.; Russowsky, D.; Montes D’Oca, M.G. Synthesis and antitumoral activity of novel analogues monastrol-fatty acids against glioma cells. MedChemComm, 2018, 9(8), 1282-1288.
[http://dx.doi.org/10.1039/C8MD00169C] [PMID: 30151081]
[30]
González-Hernández, E.; Aparicio, R.; Garayoa, M.; Montero, M.J.; Sevilla, M.Á.; Pérez-Melero, C. Dihydropyrimidine-2-thiones as Eg5 inhibitors and L-type calcium channel blockers: potential antitumour dual agents. MedChemComm, 2019, 10(9), 1589-1598.
[http://dx.doi.org/10.1039/C9MD00108E] [PMID: 31673316]
[31]
Tawfik, H.O.; El-Moselhy, T.F.; El-Din, N.S.; El-Hamamsy, M.H. Design, synthesis, and bioactivity of dihydropyrimidine derivatives as kinesin spindle protein inhibitors. Bioorg. Med. Chem., 2019, 27(23), 115126.
[http://dx.doi.org/10.1016/j.bmc.2019.115126] [PMID: 31648875]
[32]
Malik, M.S.; Seddigi, Z.S.; Bajee, S. Multicomponent access to novel proline/cyclized cysteine tethered monastrol conjugates as potential anticancer agents. J. Saudi Chem. Soc., 2019, 23(4), 503-513.
[http://dx.doi.org/10.1016/j.jscs.2019.01.003]
[33]
El-Hamamsy, M.H.; Sharafeldin, N.A.; El-Moselhy, T.F.; Tawfik, H.O. Design, synthesis, and molecular docking study of new monastrol analogues as kinesin spindle protein inhibitors. Arch. Pharm. (Weinheim), 2020, 353(8), e2000060.
[http://dx.doi.org/10.1002/ardp.202000060] [PMID: 32452567]
[34]
Chelamalla, R.; Makula, A. Virtual Screening and ADMET studies to identify KSP inhibitors as anticancer therapeutics. Int. J. Adv. Pharm. Sci., 2017, 9(1), 1-7.
[http://dx.doi.org/10.5138/09761055.2069]
[35]
Hotha, S.; Yarrow, J.C.; Yang, J.G.; Garrett, S.; Renduchintala, K.V.; Mayer, T.U.; Kapoor, T.M. HR22C16: a potent small-molecule probe for the dynamics of cell division. Angew. Chem. Int. Ed., 2003, 42(21), 2379-2382.
[http://dx.doi.org/10.1002/anie.200351173] [PMID: 12783501]
[36]
Sunder-Plassmann, N.; Sarli, V.; Gartner, M.; Utz, M.; Seiler, J.; Huemmer, S.; Mayer, T.U.; Surrey, T.; Giannis, A. Synthesis and biologi-cal evaluation of new tetrahydro-beta-carbolines as inhibitors of the mitotic kinesin Eg5. Bioorg. Med. Chem., 2005, 13(22), 6094-6111.
[http://dx.doi.org/10.1016/j.bmc.2005.06.027] [PMID: 16084101]
[37]
Barsanti, P.A.; Wang, W.; Ni, Z.J.; Duhl, D.; Brammeier, N.; Martin, E.; Bussiere, D.; Walter, A.O. The discovery of tetrahydro-beta-carbolines as inhibitors of the kinesin Eg5. Bioorg. Med. Chem. Lett., 2010, 20(1), 157-160.
[http://dx.doi.org/10.1016/j.bmcl.2009.11.012] [PMID: 19945875]
[38]
Oishi, S.; Watanabe, T.; Sawada, J.; Asai, A.; Ohno, H.; Fujii, N. Kinesin spindle protein (KSP) inhibitors with 2,3-fused indole scaffolds. J. Med. Chem., 2010, 53(13), 5054-5058.
[http://dx.doi.org/10.1021/jm100476d] [PMID: 20521839]
[39]
Liu, F.; Yu, L.Q.; Jiang, C.; Yang, L.; Wu, W.T.; You, Q.D. Discovery of tetrahydro-beta-carbolines as inhibitors of the mitotic kinesin KSP. Bioorg. Med. Chem., 2010, 18(12), 4167-4177.
[http://dx.doi.org/10.1016/j.bmc.2010.05.024] [PMID: 20537544]
[40]
Shankaraiah, N.; Nekkanti, S.; Chudasama, K.J.; Senwar, K.R.; Sharma, P.; Jeengar, M.K.; Naidu, V.G.; Srinivasulu, V.; Srinivasulu, G.; Kamal, A. Design, synthesis and anticancer evaluation of tetrahydro--carboline-hydantoin hybrids. Bioorg. Med. Chem. Lett., 2014, 24(23), 5413-5417.
[http://dx.doi.org/10.1016/j.bmcl.2014.10.038] [PMID: 25453799]
[41]
Takeuchi, T.; Oishi, S.; Watanabe, T.; Ohno, H.; Sawada, J.; Matsuno, K.; Asai, A.; Asada, N.; Kitaura, K.; Fujii, N. Structure-activity rela-tionships of carboline and carbazole derivatives as a novel class of ATP-competitive kinesin spindle protein inhibitors. J. Med. Chem., 2011, 54(13), 4839-4846.
[http://dx.doi.org/10.1021/jm200448n] [PMID: 21599002]
[42]
Takenaga, M.; Yamamoto, Y.; Takeuchi, T.; Ohta, Y.; Tokura, Y.; Hamaguchi, A.; Asai, D.; Nakashima, H.; Oishi, S.; Fujii, N. Potential new chemotherapy strategy for human ovarian carcinoma with a novel KSP inhibitor. Biochem. Biophys. Res. Commun., 2015, 463(3), 222-228.
[http://dx.doi.org/10.1016/j.bbrc.2015.05.029] [PMID: 25998394]
[43]
Kojima-tsuchiya, S.; Ohta, Y.; Takenaga, M.; Niimi, J.; Watanabe, D.; Tsunoda, S.; Ootaki, M.; Oishi, S.; Fujii, N.; Matsumoto, N.; Tsuga-wa, K. A novel KSP inhibitor, KPYB10602, induces mitotic arrest and cell death in breast cancer cells. J. St. Marianna Univ., 2016, 7(2), 105-116.
[http://dx.doi.org/10.17264/stmarieng.7.105]
[44]
Samundeeswari, S.; Chougala, B.; Holiyachi, M.; Shastri, L.; Kulkarni, M.; Dodamani, S.; Jalalpur, S.; Joshi, S.; Dixit, S.; Sunagar, V.; Hunnur, R. Design and synthesis of novel phenyl -1, 4-beta-carboline-hybrid molecules as potential anticancer agents. Eur. J. Med. Chem., 2017, 128, 123-139.
[http://dx.doi.org/10.1016/j.ejmech.2017.01.014] [PMID: 28171832]
[45]
Abdelsalam, M.A. AboulWafa, O.M.; M Badawey, E.A.; El-Shoukrofy, M.S.; El-Miligy, M.M.; Gouda, N.; Elaasser, M.M. Design, syn-thesis, anticancer screening, docking studies and in silico ADME prediction of some -carboline derivatives. Future Med. Chem., 2018, 10(10), 1159-1175.
[http://dx.doi.org/10.4155/fmc-2017-0206] [PMID: 29787297]
[46]
Abdelsalam, M.A. AboulWafa, O.M.; Badawey, E.A.; El-Shoukrofy, M.S.; El-Miligy, M.M.; Gouda, N. Design and synthesis of some -carboline derivatives as multi-target anticancer agents. Future Med. Chem., 2018, 10(24), 2791-2814.
[http://dx.doi.org/10.4155/fmc-2018-0226] [PMID: 30539666]
[47]
Jiang, C.; Yang, L.; Wu, W.T.; Guo, Q.L.; You, Q.D. CPUYJ039, a newly synthesized benzimidazole-based compound, is proved to be a novel inducer of apoptosis in HCT116 cells with potent KSP inhibitory activity. J. Pharm. Pharmacol., 2011, 63(11), 1462-1469.
[http://dx.doi.org/10.1111/j.2042-7158.2011.01350.x] [PMID: 21988427]
[48]
Carbajales, C.; Prado, M.Á.; Gutiérrez-de-Terán, H.; Cores, A.; Azuaje, J.; Novio, S.; Nuñez, M.J.; Fernández-García, B.; Sotelo, E. Gar-cía-Mera, X.; Sánchez-Lazo, P.; Freire-Garabal, M.; Coelho, A. Structure-based design of new KSP-Eg5 inhibitors assisted by a targeted multicomponent reaction. Chem. Bio. Chem., 2014, 15(10), 1471-1480.
[http://dx.doi.org/10.1002/cbic.201402089] [PMID: 24943831]
[49]
Abd El-All, A.S.; Magd-El-Din, A.A.; Ragab, F.A.; ElHefnawi, M.; Abdalla, M.M.; Galal, S.A.; El-Rashedy, A.A. New benzimidazoles and their antitumor effects with Aurora A kinase and KSP inhibitory activities. Arch. Pharm. (Weinheim), 2015, 348(7), 475-486.
[http://dx.doi.org/10.1002/ardp.201400441] [PMID: 25900113]
[50]
El-din, A.A.M.; El-serwy, W.S.; El-all, A.S.A. Synthesis, molecular modeling and bioevaluation of new benzimidazole derivatives as dual KSP (kinesin spindle protein) and aurora A kinase inhibitors for antitumor activity. J. Innov. Pharm. Biol. Sci., 2017, 4, 17-27.
[51]
Nagarajan, S.; Skoufias, D.A.; Kozielski, F.; Pae, A.N. Receptor-ligand interaction-based virtual screening for novel Eg5/kinesin spindle protein inhibitors. J. Med. Chem., 2012, 55(6), 2561-2573.
[http://dx.doi.org/10.1021/jm201290v] [PMID: 22309208]
[52]
Parrish, C.A.; Adams, N.D.; Auger, K.R.; Burgess, J.L.; Carson, J.D.; Chaudhari, A.M.; Copeland, R.A.; Diamond, M.A.; Donatelli, C.A.; Duffy, K.J.; Faucette, L.F.; Finer, J.T.; Huffman, W.F.; Hugger, E.D.; Jackson, J.R.; Knight, S.D.; Luo, L.; Moore, M.L.; Newlander, K.A.; Ridgers, L.H.; Sakowicz, R.; Shaw, A.N.; Sung, C.M.; Sutton, D.; Wood, K.W.; Zhang, S.Y.; Zimmerman, M.N.; Dhanak, D. Novel ATP-competitive kinesin spindle protein inhibitors. J. Med. Chem., 2007, 50(20), 4939-4952.
[http://dx.doi.org/10.1021/jm070435y] [PMID: 17725339]
[53]
Holland, J.P.; Kang, A.; Cohrs, S.; Selivanova, S.V.; Milicevic Sephton, S.; Betzel, T.; Frey, D.; Wieser, M.; Jaussi, R.; Kammerer, R.A.; Schibli, R.; Fischer, E. Synthesis and evaluation of biphenyl compounds as kinesin spindle protein inhibitors. Chem. Biodivers., 2013, 10(4), 538-555.
[http://dx.doi.org/10.1002/cbdv.201200400] [PMID: 23576341]
[54]
Sawada, J.I.; Osawa, A.; Takeuchi, T.; Kaneda, M.; Oishi, S.; Fujii, N.; Asai, A.; Tanino, K.; Namba, K. Functional 1,3a,6a-triazapentalene scaffold: Design of fluorescent probes for kinesin spindle protein (KSP). Bioorg. Med. Chem. Lett., 2016, 26(23), 5765-5769.
[http://dx.doi.org/10.1016/j.bmcl.2016.10.047] [PMID: 27793568]
[55]
Takeuchi, T.; Oishi, S.; Kaneda, M.; Ohno, H.; Nakamura, S.; Nakanishi, I.; Yamane, M.; Sawada, J.; Asai, A.; Fujii, N. Kinesin spindle protein inhibitors with diaryl amine scaffolds: crystal packing analysis for improved aqueous solubility. ACS Med. Chem. Lett., 2014, 5(5), 566-571.
[http://dx.doi.org/10.1021/ml500016j] [PMID: 24900881]
[56]
Takeuchi, T.; Oishi, S.; Kaneda, M.; Misu, R.; Ohno, H.; Sawada, J.; Asai, A.; Nakamura, S.; Nakanishi, I.; Fujii, N. Optimization of diaryl amine derivatives as kinesin spindle protein inhibitors. Bioorg. Med. Chem., 2014, 22(12), 3171-3179.
[http://dx.doi.org/10.1016/j.bmc.2014.04.008] [PMID: 24794744]
[57]
Wang, F.; Good, J.A.D.; Rath, O.; Kaan, H.Y.; Sutcliffe, O.B.; Mackay, S.P.; Kozielski, F. Triphenylbutanamines: kinesin spindle protein inhibitors with in vivo antitumor activity. J. Med. Chem., 2012, 55(4), 1511-1525.
[http://dx.doi.org/10.1021/jm201195m] [PMID: 22248262]
[58]
Good, J.A.; Wang, F.; Rath, O.; Kaan, H.Y.; Talapatra, S.K.; Podgórski, D.; MacKay, S.P.; Kozielski, F. Optimized S-trityl-L-cysteine-based inhibitors of kinesin spindle protein with potent in vivo antitumor activity in lung cancer xenograft models. J. Med. Chem., 2013, 56(5), 1878-1893.
[http://dx.doi.org/10.1021/jm3014597] [PMID: 23394180]
[59]
Ogo, N.; Ishikawa, Y.; Sawada, J.; Matsuno, K.; Hashimoto, A.; Asai, A. Structure-guided design of novel l-cysteine derivatives as potent KSP inhibitors. ACS Med. Chem. Lett., 2015, 6(9), 1004-1009.
[http://dx.doi.org/10.1021/acsmedchemlett.5b00221] [PMID: 26396688]
[60]
Dong, J.J.; Li, Q.S.; Liu, Z.P.; Wang, S.F.; Zhao, M.Y.; Yang, Y.H.; Wang, X.M.; Zhu, H.L. Synthesis, biological evaluation and molecular docking studies of flavone and isoflavone derivatives as a novel class of KSP (kinesin spindle protein) inhibitors. Eur. J. Med. Chem., 2013, 70, 427-433.
[http://dx.doi.org/10.1016/j.ejmech.2013.09.042] [PMID: 24184776]
[61]
Theoclitou, M.E.; Aquila, B.; Block, M.H.; Brassil, P.J.; Castriotta, L.; Code, E.; Collins, M.P.; Davies, A.M.; Deegan, T.; Ezhuthachan, J.; Filla, S.; Freed, E.; Hu, H.; Huszar, D.; Jayaraman, M.; Lawson, D.; Lewis, P.M.; Nadella, M.V.; Oza, V.; Padmanilayam, M.; Pontz, T.; Ronco, L.; Russell, D.; Whitston, D.; Zheng, X. Discovery of (+)-N-(3-aminopropyl)-N-[1-(5-benzyl-3-methyl-4-oxo-[1,2]thiazolo[5,4-d]pyrimidin-6-yl)-2-methylpropyl]-4-methylbenzamide (AZD4877), a kinesin spindle protein inhibitor and potential anticancer agent. J. Med. Chem., 2011, 54(19), 6734-6750.
[http://dx.doi.org/10.1021/jm200629m] [PMID: 21899292]
[62]
Marquis, L.; Tran, M.; Choi, W.; Lee, I.L.; Huszar, D.; Siefker-Radtke, A.; Dinney, C.; McConkey, D.J. p63 expression correlates with sensitivity to the Eg5 inhibitor ZD4877 in bladder cancer cells. Cancer Biol. Ther., 2012, 13(7), 477-486.
[http://dx.doi.org/10.4161/cbt.19590] [PMID: 22361733]
[63]
Fu, R.G.; You, Q.D.; Yang, L.; Wu, W.T.; Jiang, C.; Xu, X.L. Design, synthesis and bioevaluation of dihydropyrazolo[3,4-b]pyridine and benzo[4,5]imidazo[1,2-a]pyrimidine compounds as dual KSP and Aurora-A kinase inhibitors for anti-cancer agents. Bioorg. Med. Chem., 2010, 18(22), 8035-8043.
[http://dx.doi.org/10.1016/j.bmc.2010.09.020] [PMID: 20934346]
[64]
Muthuraja, P.; Veeramani, V.; Prakash, S.; Himesh, M.; Venkatasubramanian, U.; Manisankar, P. Structure-activity relationship of pyrazo-lo pyrimidine derivatives as inhibitors of mitotic kinesin Eg5 and anticancer agents. Bioorg. Chem., 2019, 84, 493-504.
[http://dx.doi.org/10.1016/j.bioorg.2018.12.014] [PMID: 30594885]
[65]
Muthuraja, P.; Himesh, M.; Prakash, S.; Venkatasubramanian, U.; Manisankar, P. Synthesis of N-(1-(6-acetamido-5-phenylpyrimidin-4-yl) piperidin-3-yl) amide derivatives as potential inhibitors for mitotic kinesin spindle protein. Eur. J. Med. Chem., 2018, 148, 106-115.
[http://dx.doi.org/10.1016/j.ejmech.2018.02.010] [PMID: 29454915]
[66]
Makala, H.; Ulaganathan, V. Identification of novel scaffolds to inhibit human mitotic kinesin Eg5 targeting the second allosteric binding site using in silico methods. J. Recept. Signal Transduct. Res., 2018, 38(1), 12-19.
[http://dx.doi.org/10.1080/10799893.2017.1387922] [PMID: 29041840]
[67]
Johnson, R.K.; McCabe, F.L.; Whitacre, M. SB-715992, a potent and selective inhibitor of the mitotic kinesin KSP, demonstrates broad-spectrum activity in advanced murine tumors and human tumor xenografts. Proc. Am. Assoc. Cancer Res., 2002, 43, 269.
[68]
Lad, L.; Luo, L.; Carson, J.D.; Wood, K.W.; Hartman, J.J.; Copeland, R.A.; Sakowicz, R. Mechanism of inhibition of human KSP by ispinesib. Biochemistry, 2008, 47(11), 3576-3585.
[http://dx.doi.org/10.1021/bi702061g] [PMID: 18290633]
[69]
Jiang, C.; Yang, L.; Wu, W.T.; Guo, Q.L.; You, Q.D. De novo design, synthesis and biological evaluation of 1,4-dihydroquinolin-4-ones and 1,2,3,4-tetrahydroquinazolin-4-ones as potent kinesin spindle protein (KSP) inhibitors. Bioorg. Med. Chem., 2011, 19(18), 5612-5627.
[http://dx.doi.org/10.1016/j.bmc.2011.07.029] [PMID: 21856161]
[70]
Schiemann, K.; Finsinger, D.; Zenke, F.; Amendt, C.; Knöchel, T.; Bruge, D.; Buchstaller, H.P.; Emde, U.; Stähle, W.; Anzali, S. The dis-covery and optimization of hexahydro-2H-pyrano[3,2-c]quinolines (HHPQs) as potent and selective inhibitors of the mitotic kinesin-5. Bioorg. Med. Chem. Lett., 2010, 20(5), 1491-1495.
[http://dx.doi.org/10.1016/j.bmcl.2010.01.110] [PMID: 20149654]
[71]
Basso, A.D.; Liu, M.; Dai, C.; Gray, K.; Nale, L.; Tevar, S.; Lee, S.; Liang, L.; Ponery, A.; Yaremko, B.; Smith, E.; Tang, H.; Sheth, P.R.; Siddiqui, M.A.; Hicklin, D.J.; Kirschmeier, P. SCH 2047069, a novel oral kinesin spindle protein inhibitor, shows single-agent antitumor activity and enhances the efficacy of chemotherapeutics. Mol. Cancer Ther., 2010, 9(11), 2993-3002.
[http://dx.doi.org/10.1158/1535-7163.MCT-10-0548] [PMID: 20978164]
[72]
Yamamoto, J.; Amishiro, N.; Kato, K.; Ohta, Y.; Ino, Y.; Araki, M.; Tsujita, T.; Okamoto, S.; Takahashi, T.; Kusaka, H.; Akinaga, S.; Yamashita, Y.; Nakai, R.; Murakata, C. Synthetic studies on mitotic kinesin Eg5 inhibitors: synthesis and structure-activity relationships of novel 2,4,5-substituted-1,3,4-thiadiazoline derivatives. Bioorg. Med. Chem. Lett., 2014, 24(16), 3961-3963.
[http://dx.doi.org/10.1016/j.bmcl.2014.06.034] [PMID: 25001485]
[73]
Ye, X.S.; Fan, L.; Van Horn, R.D.; Nakai, R.; Ohta, Y.; Akinaga, S.; Murakata, C.; Yamashita, Y.; Yin, T.; Credille, K.M.; Donoho, G.P.; Merzoug, F.F.; Li, H.; Aggarwal, A.; Blanchard, K.; Westin, E.H. A novel Eg5 inhibitor (LY2523355) causes mitotic arrest and apoptosis in cancer cells and shows potent antitumor activity in xenograft tumor models. Mol. Cancer Ther., 2015, 14(11), 2463-2472.
[http://dx.doi.org/10.1158/1535-7163.MCT-15-0241] [PMID: 26304237]
[74]
Mansoor, U.F.; Angeles, A.R.; Dai, C.; Yang, L.; Vitharana, D.; Basso, A.D.; Gray, K.; Tang, H.; Liu, M.; Liang, L.; Allbritton, O.; Sid-diqui, M.A. Discovery of novel spiro 1,3,4-thiadiazolines as potent, orally bioavailable and brain penetrant KSP inhibitors. Bioorg. Med. Chem., 2015, 23(10), 2424-2434.
[http://dx.doi.org/10.1016/j.bmc.2015.03.052] [PMID: 25868746]
[75]
De Monte, C.; Carradori, S.; Secci, D.; D’Ascenzio, M.; Guglielmi, P.; Mollica, A.; Morrone, S.; Scarpa, S.; Aglianò, A.M.; Giantulli, S.; Silvestri, I. Synthesis and pharmacological screening of a large library of 1,3,4-thiadiazolines as innovative therapeutic tools for the treat-ment of prostate cancer and melanoma. Eur. J. Med. Chem., 2015, 105, 245-262.
[http://dx.doi.org/10.1016/j.ejmech.2015.10.023] [PMID: 26498571]
[76]
Khathi, S.P.; Chandrasekaran, B.; Karunanidhi, S.; Tham, C.L.; Kozielski, F.; Sayyad, N.; Karpoormath, R. Design and synthesis of novel thiadiazole-thiazolone hybrids as potential inhibitors of the human mitotic kinesin Eg5. Bioorg. Med. Chem. Lett., 2018, 28(17), 2930-2938.
[http://dx.doi.org/10.1016/j.bmcl.2018.07.007] [PMID: 30055887]
[77]
Ishikawa, K.; Tohyama, K.; Mitsuhashi, S.; Maruta, S. Photocontrol of the mitotic kinesin Eg5 using a novel S-trityl-L-cysteine analogue as a photochromic inhibitor. J. Biochem., 2014, 155(4), 257-263.
[http://dx.doi.org/10.1093/jb/mvu004] [PMID: 24451491]
[78]
Sadakane, K.; Takaichi, M.; Maruta, S. Photo-control of the mitotic kinesin Eg5 using a novel photochromic inhibitor composed of a spi-ropyran derivative. J. Biochem., 2018, 164(3), 239-246.
[http://dx.doi.org/10.1093/jb/mvy046] [PMID: 29718428]
[79]
Sadakane, K.; Alrazi, I.M.D.; Maruta, S. Highly efficient photocontrol of mitotic kinesin Eg5 ATPase activity using a novel photochromic compound composed of two azobenzene derivatives. J. Biochem., 2018, 164(4), 295-301.
[http://dx.doi.org/10.1093/jb/mvy051] [PMID: 29860530]
[80]
Nakazawa, J.; Yajima, J.; Usui, T.; Ueki, M.; Takatsuki, A.; Imoto, M.; Toyoshima, Y.Y.; Osada, H. A novel action of terpendole E on the motor activity of mitotic Kinesin Eg5. Chem. Biol., 2003, 10(2), 131-137.
[http://dx.doi.org/10.1016/S1074-5521(03)00020-6] [PMID: 12618185]
[81]
DeBonis, S.; Skoufias, D.A.; Lebeau, L.; Lopez, R.; Robin, G.; Margolis, R.L.; Wade, R.H.; Kozielski, F. In vitro screening for inhibitors of the human mitotic kinesin Eg5 with antimitotic and antitumor activities. Mol. Cancer Ther., 2004, 3(9), 1079-1090.
[PMID: 15367702]
[82]
Churruca, F.; Fousteris, M.; Ishikawa, Y.; Rekowski, M.; Hounsou, C.; Surrey, T.; Giannis, A. A novel approach to indoloditerpenes by Nazarov photocyclization: synthesis and biological investigations of terpendole E analogues. Org. Lett., 2010, 12(9), 2096-2099.
[http://dx.doi.org/10.1021/ol100579w] [PMID: 20387880]
[83]
Shidaifat, F.; Canatan, H.; Kulp, S.K.; Sugimoto, Y.; Zhang, Y.; Brueggemeier, R.W.; Somers, W.J.; Chang, W.Y.; Wang, H.C.; Lin, Y.C. Gossypol arrests human benign prostatic hyperplastic cell growth at G0/G1 phase of the cell cycle. Anticancer Res., 1997, 17(2A), 1003-1009.
[PMID: 9137441]
[84]
Heist, R.S.; Fain, J.; Chinnasami, B.; Khan, W.; Molina, J.R.; Sequist, L.V.; Temel, J.S.; Fidias, P.; Brainerd, V.; Leopold, L.; Lynch, T.J. Phase I/II study of AT-101 with topotecan in relapsed and refractory small cell lung cancer. J. Thorac. Oncol., 2010, 5(10), 1637-1643.
[http://dx.doi.org/10.1097/JTO.0b013e3181e8f4dc] [PMID: 20808253]
[85]
Ready, N.; Karaseva, N.A.; Orlov, S.V.; Luft, A.V.; Popovych, O.; Holmlund, J.T.; Wood, B.A.; Leopold, L. Double-blind, placebo-controlled, randomized phase 2 study of the proapoptotic agent AT-101 plus docetaxel, in second-line non-small cell lung cancer. J. Thorac. Oncol., 2011, 6(4), 781-785.
[http://dx.doi.org/10.1097/JTO.0b013e31820a0ea6] [PMID: 21289522]
[86]
Busch, T.; Dräger, G.; Kunst, E.; Benson, H.; Sasse, F.; Siems, K.; Kirschning, A. Synthesis and antiproliferative activity of new to-nantzitlolone-derived diterpene derivatives. Org. Biomol. Chem., 2016, 14(38), 9040-9045.
[http://dx.doi.org/10.1039/C6OB01697A] [PMID: 27604289]
[87]
Ogunwa, T.H.; Taii, K.; Sadakane, K.; Kawata, Y.; Maruta, S.; Miyanishi, T. Morelloflavone as a novel inhibitor of mitotic kinesin Eg5. J. Biochem., 2019, 166(2), 129-137.
[http://dx.doi.org/10.1093/jb/mvz015] [PMID: 30785183]
[88]
Farias, K.; da Costa, R.F.; Meira, A.S.; Diniz-Filho, J.; Bezerra, E.M.; Freire, V.N.; Guest, P.; Nikahd, M.; Ma, X.; Gardiner, M.G.; Banwell, M.G.; de Oliveira, M.D.C.F.; de Moraes, M.O.; do Ó Pessoa, C. Antitumor potential of the isoflavonoids (+)- and (-)-2,3,9-trimethoxypterocarpan: Mechanism-of-action studies. ACS Med. Chem. Lett., 2020, 11(6), 1274-1280.
[http://dx.doi.org/10.1021/acsmedchemlett.0c00097] [PMID: 32551011]
[89]
Khoury, H.J.; Garcia-Manero, G.; Borthakur, G.; Kadia, T.; Foudray, M.C.; Arellano, M.; Langston, A.; Bethelmie-Bryan, B.; Rush, S.; Litwiler, K.; Karan, S.; Simmons, H.; Marcus, A.I.; Ptaszynski, M.; Kantarjian, H. A phase 1 dose-escalation study of ARRY-520, a kine-sin spindle protein inhibitor, in patients with advanced myeloid leukemias. Cancer, 2012, 118(14), 3556-3564.
[http://dx.doi.org/10.1002/cncr.26664] [PMID: 22139909]
[90]
LoRusso, P.M.; Goncalves, P.H.; Casetta, L.; Carter, J.A.; Litwiler, K.; Roseberry, D.; Rush, S.; Schreiber, J.; Simmons, H.M.; Ptaszynski, M.; Sausville, E.A. First-in-human phase 1 study of filanesib (ARRY-520), a kinesin spindle protein inhibitor, in patients with advanced solid tumors. Invest. New Drugs, 2015, 33(2), 440-449.
[http://dx.doi.org/10.1007/s10637-015-0211-0] [PMID: 25684345]
[91]
Shah, J.J.; Kaufman, J.L.; Zonder, J.A.; Cohen, A.D.; Bensinger, W.I.; Hilder, B.W.; Rush, S.A.; Walker, D.H.; Tunquist, B.J.; Litwiler, K.S.; Ptaszynski, M.; Orlowski, R.Z.; Lonial, S. A Phase 1 and 2 study of Filanesib alone and in combination with low-dose dexame-thasone in relapsed/refractory multiple myeloma. Cancer, 2017, 123(23), 4617-4630.
[http://dx.doi.org/10.1002/cncr.30892] [PMID: 28817190]
[92]
Chari, A.; Htut, M.; Zonder, J.A.; Fay, J.W.; Jakubowiak, A.J.; Levy, J.B.; Lau, K.; Burt, S.M.; Tunquist, B.J.; Hilder, B.W.; Rush, S.A.; Walker, D.H.; Ptaszynski, M.; Kaufman, J.L. A phase 1 dose-escalation study of filanesib plus bortezomib and dexamethasone in patients with recurrent/refractory multiple myeloma. Cancer, 2016, 122(21), 3327-3335.
[http://dx.doi.org/10.1002/cncr.30174] [PMID: 27433944]
[93]
Lee, H.C.; Shah, J.J.; Feng, L.; Manasanch, E.E.; Lu, R.; Morphey, A.; Crumpton, B.; Patel, K.K.; Wang, M.L.; Alexanian, R.; Thomas, S.K.; Weber, D.M.; Orlowski, R.Z. A phase 1 study of filanesib, carfilzomib, and dexamethasone in patients with relapsed and/or refracto-ry multiple myeloma. Blood Cancer J., 2019, 9(10), 80.
[http://dx.doi.org/10.1038/s41408-019-0240-6] [PMID: 31575851]
[94]
Ocio, E.M.; Motlló, C.; Rodríguez-Otero, P.; Martínez-López, J.; Cejalvo, M.J.; Martín-Sánchez, J.; Bladé, J.; García-Malo, M.D.; Dourdil, M.V.; García-Mateo, A.; de Arriba, F.; García-Sanz, R.; de la Rubia, J.; Oriol, A.; Lahuerta, J.J.; San-Miguel, J.F.; Mateos, M.V. Filanesib in combination with pomalidomide and dexamethasone in refractory MM patients: safety and efficacy, and association with alpha 1-acid gly-coprotein (AAG) levels. Phase Ib/II Pomdefil clinical trial conducted by the Spanish MM group. Br. J. Haematol., 2021, 192(3), 522-530.
[http://dx.doi.org/10.1111/bjh.16788] [PMID: 32501528]
[95]
Wakui, H.; Yamamoto, N.; Kitazono, S.; Mizugaki, H.; Nakamichi, S.; Fujiwara, Y.; Nokihara, H.; Yamada, Y.; Suzuki, K.; Kanda, H.; Akinaga, S.; Tamura, T. A phase 1 and dose-finding study of LY2523355 (litronesib), an Eg5 inhibitor, in Japanese patients with ad-vanced solid tumors. Cancer Chemother. Pharmacol., 2014, 74(1), 15-23.
[http://dx.doi.org/10.1007/s00280-014-2467-z] [PMID: 24752449]
[96]
Shih, K.C.; Infante, J.R.; Papadopoulos, K.P.; Bendell, J.C.; Tolcher, A.W.; Burris, H.A.; Beeram, M.; Jackson, L.; Arcos, R.; Westin, E.H.; Farrington, D.; McGlothlin, A.; Hynes, S.; Leohr, J.; Brandt, J.T.; Nasir, A.; Patnaik, A. A phase I dose-escalation study of LY2523355, an Eg5 inhibitor, administered either on days 1, 5, and 9; days 1 and 8; or days 1 and 5 with pegfilgrastim (peg) every 21 days (NCT01214642). J. Clin. Oncol., 2011, 29(15)(Suppl.), 2600.
[http://dx.doi.org/10.1200/jco.2011.29.15_suppl.2600]
[97]
Infante, J.R.; Patnaik, A.; Verschraegen, C.F.; Olszanski, A.J.; Shaheen, M.; Burris, H.A.; Tolcher, A.W.; Papadopoulos, K.P.; Beeram, M.; Hynes, S.M.; Leohr, J.; Lin, A.B.; Li, L.Q.; McGlothlin, A.; Farrington, D.L.; Westin, E.H.; Cohen, R.B. Two Phase 1 dose-escalation stud-ies exploring multiple regimens of litronesib (LY2523355), an Eg5 inhibitor, in patients with advanced cancer. Cancer Chemother. Pharmacol., 2017, 79(2), 315-326.
[http://dx.doi.org/10.1007/s00280-016-3205-5] [PMID: 28097385]
[98]
Jackson, J.R.; Gilmartin, A.; Dhanak, D. A second generation KSP inhibitor, SB-743921, is a highly potent and active therapeutic in pre-clinical models of cancer. Clin. Cancer Res., 2006, 12(19)(Suppl.)
[99]
Souid, A.K.; Dubowy, R.L.; Ingle, A.M.; Conlan, M.G.; Sun, J.; Blaney, S.M.; Adamson, P.C. A pediatric phase I trial and pharmacokinetic study of ispinesib: a Children’s Oncology Group phase I consortium study. Pediatr. Blood Cancer, 2010, 55(7), 1323-1328.
[http://dx.doi.org/10.1002/pbc.22609] [PMID: 20712019]
[100]
Burris, H.A., III; Jones, S.F.; Williams, D.D.; Kathman, S.J.; Hodge, J.P.; Pandite, L.; Ho, P.T.; Boerner, S.A.; Lorusso, P. A phase I study of ispinesib, a kinesin spindle protein inhibitor, administered weekly for three consecutive weeks of a 28-day cycle in patients with solid tumors. Invest. New Drugs, 2011, 29(3), 467-472.
[http://dx.doi.org/10.1007/s10637-009-9374-x] [PMID: 20069338]
[101]
Chen, L.C.; Rosen, L.S.; Iyengar, T.; Goldman, J.W.; Savage, R.; Kazakin, J.; Chan, T.C.K.; Schwartz, B.E.; Abbadessa, G.; Von Hoff, D.D. First-in-human study with ARQ 621, a novel inhibitor of Eg5: Final results from the solid tumors cohort. J. Clin. Oncol., 2011, 29(15)(Suppl.), 3076.
[http://dx.doi.org/10.1200/jco.2011.29.15_suppl.3076]
[102]
Mross, K.B.; Scharr, D.; Richly, H.; Frost, A.; Bauer, S.; Krauss, B.; Krauss, R.; Mais, A.; Hauns, B.; Hentsch, B.; Baumgartner, R.; Scheu-len, M.E. First-in-human study of 4SC-205 (AEGIS), a novel oral inhibitor of Eg5 kinesin spindle protein. J. Clin. Oncol., 2014, 32(15)(Suppl.), 2564.
[http://dx.doi.org/10.1200/jco.2014.32.15_suppl.2564]
[103]
U.S. National Library of Medicine ClinicalTrials.gov. Available from: https://clinicaltrials.gov/ (Accessed on: May 05, 2021)

Rights & Permissions Print Cite
© 2025 Bentham Science Publishers | Privacy Policy
Request history8.2.27PHP Version317msRequest Duration28MBMemory UsageGET article/{article_id}/{param?}Route
  • warninglog[23:26:44] LOG.warning: Optional parameter $article_id declared before required parameter $request i...
  • warninglog[23:26:44] LOG.warning: Function strftime() is deprecated in /home/alphaeurekaselec/public_html/stor...
  • warninglog[23:26:44] LOG.warning: trim(): Passing null to parameter #1 ($string) of type string is deprecated ...
  • warninglog[23:26:44] LOG.warning: Function strftime() is deprecated in /home/alphaeurekaselec/public_html/stor...
  • Booting (95.63ms)time
  • Application (221ms)time
  • 1 x Application (69.79%)
    221ms
    1 x Booting (30.2%)
    95.63ms
    14 templates were rendered
    • articlearticle.blade.php#?blade
    • includes.article_top_bannerarticle_top_banner.blade.php#?blade
    • includes.article_referencearticle_reference.blade.php#?blade
    • export_citation_formexport_citation_form.blade.php#?blade
    • includes.article_bottom_bannerarticle_bottom_banner.blade.php#?blade
    • includes.inc_related_journalsinc_related_journals.blade.php#?blade
    • includes.inc_related_ebooksinc_related_ebooks.blade.php#?blade
    • includes.journal_rightmenujournal_rightmenu.blade.php#?blade
    • includes.journal_right_bannerjournal_right_banner.blade.php#?blade
    • layouts.appapp.blade.php#?blade
    • layouts._login_access_login_access.blade.php#?blade
    • layouts._header_header.blade.php#?blade
    • layouts._main_menu_main_menu.blade.php#?blade
    • layouts._footer_menu_footer_menu.blade.php#?blade
    uri
    GET article/{article_id}/{param?}
    middleware
    web, check_user_access
    controller
    App\Http\Controllers\ArticleController@GetArticleDetails
    namespace
    App\Http\Controllers
    where
    as
    article
    file
    app/Http/Controllers/ArticleController.php:1974-2510
    37 statements were executed, 4 of which were duplicates, 33 unique. Show only duplicated142ms
    • Connection Establishedalphaeurekaselec_live_10_06_2022UserAccessCheck.php#24
      Backtrace
      • 9. middleware::check_user_access:24
      • 10. vendor/laravel/framework/src/Illuminate/Pipeline/Pipeline.php:183
      • 11. vendor/laravel/framework/src/Illuminate/Routing/Middleware/SubstituteBindings.php:50
      • 12. vendor/laravel/framework/src/Illuminate/Pipeline/Pipeline.php:183
      • 13. vendor/laravel/framework/src/Illuminate/Foundation/Http/Middleware/VerifyCsrfToken.php:88
    • INSERT INTO visitor_ip_address (ip_address,visitor_agent,visitor_count, created_on,updated_on) VALUES ('51413955','',1,1739834804,1739834804) ON DUPLICATE KEY UPDATE visitor_count=visitor_count + 1, updated_on=1739834804
      1.1msalphaeurekaselec_live_10_06_2022UserAccessCheck.php#24
      Backtrace
      • 11. middleware::check_user_access:24
      • 12. vendor/laravel/framework/src/Illuminate/Pipeline/Pipeline.php:183
      • 13. vendor/laravel/framework/src/Illuminate/Routing/Middleware/SubstituteBindings.php:50
      • 14. vendor/laravel/framework/src/Illuminate/Pipeline/Pipeline.php:183
      • 15. vendor/laravel/framework/src/Illuminate/Foundation/Http/Middleware/VerifyCsrfToken.php:88
    • INSERT INTO visitor_ip_address_detail (ip_address,visitor_url,visitor_count, created_on,updated_on) VALUES ('51413955','/article/120267',1,1739834804,1739834804)
      150μsalphaeurekaselec_live_10_06_2022UserAccessCheck.php#27
      Backtrace
      • 11. middleware::check_user_access:27
      • 12. vendor/laravel/framework/src/Illuminate/Pipeline/Pipeline.php:183
      • 13. vendor/laravel/framework/src/Illuminate/Routing/Middleware/SubstituteBindings.php:50
      • 14. vendor/laravel/framework/src/Illuminate/Pipeline/Pipeline.php:183
      • 15. vendor/laravel/framework/src/Illuminate/Foundation/Http/Middleware/VerifyCsrfToken.php:88
    • (select `user_id`, `to_ip`, `from_ip` from (select user_id, to_ip, from_ip FROM user_access_journal_volume_trail WHERE to_ip >= 51413955 ORDER BY to_ip ASC LIMIT 1) as `tjv` where `from_ip` <= 51413955) union (select `user_id`, `to_ip`, `from_ip` from (select user_id, to_ip, from_ip FROM user_access_journal_volume_corporate WHERE to_ip >= 51413955 ORDER BY to_ip ASC LIMIT 1) as `tjv` where `from_ip` <= 51413955) union (select `user_id`, `to_ip`, `from_ip` from (select user_id, to_ip, from_ip FROM user_access_journal_volume_token WHERE to_ip >= 51413955 ORDER BY to_ip ASC LIMIT 1) as `tjv` where `from_ip` <= 51413955) union (select `user_id`, `to_ip`, `from_ip` from (select user_id, to_ip, from_ip FROM user_access_ebook_volume_trail WHERE to_ip >= 51413955 ORDER BY to_ip ASC LIMIT 1) as `tjv` where `from_ip` <= 51413955) union (select `user_id`, `to_ip`, `from_ip` from (select user_id, to_ip, from_ip FROM user_access_ebook_volume_corporate WHERE to_ip >= 51413955 ORDER BY to_ip ASC LIMIT 1) as `tjv` where `from_ip` <= 51413955) union (select `user_id`, `to_ip`, `from_ip` from (select user_id, to_ip, from_ip FROM user_access_ebook_volume_token WHERE to_ip >= 51413955 ORDER BY to_ip ASC LIMIT 1) as `tjv` where `from_ip` <= 51413955) union (select `user_id`, `to_ip`, `from_ip` from (select user_id, to_ip, from_ip FROM user_access_issue_trail WHERE to_ip >= 51413955 ORDER BY to_ip ASC LIMIT 1) as `tjv` where `from_ip` <= 51413955) union (select `user_id`, `to_ip`, `from_ip` from (select user_id, to_ip, from_ip FROM user_access_issue_corporate WHERE to_ip >= 51413955 ORDER BY to_ip ASC LIMIT 1) as `tjv` where `from_ip` <= 51413955) union (select `user_id`, `to_ip`, `from_ip` from (select user_id, to_ip, from_ip FROM user_access_issue_token WHERE to_ip >= 51413955 ORDER BY to_ip ASC LIMIT 1) as `tjv` where `from_ip` <= 51413955) union (select `user_id`, `to_ip`, `from_ip` from (select user_id, to_ip, from_ip FROM user_access_article_trail WHERE to_ip >= 51413955 ORDER BY to_ip ASC LIMIT 1) as `tjv` where `from_ip` <= 51413955) union (select `user_id`, `to_ip`, `from_ip` from (select user_id, to_ip, from_ip FROM user_access_article_corporate WHERE to_ip >= 51413955 ORDER BY to_ip ASC LIMIT 1) as `tjv` where `from_ip` <= 51413955) union (select `user_id`, `to_ip`, `from_ip` from (select user_id, to_ip, from_ip FROM user_access_article_token WHERE to_ip >= 51413955 ORDER BY to_ip ASC LIMIT 1) as `tjv` where `from_ip` <= 51413955) union (select `user_id`, `to_ip`, `from_ip` from (select user_id, to_ip, from_ip FROM user_access_chapter_trail WHERE to_ip >= 51413955 ORDER BY to_ip ASC LIMIT 1) as `tjv` where `from_ip` <= 51413955) union (select `user_id`, `to_ip`, `from_ip` from (select user_id, to_ip, from_ip FROM user_access_chapter_corporate WHERE to_ip >= 51413955 ORDER BY to_ip ASC LIMIT 1) as `tjv` where `from_ip` <= 51413955) union (select `user_id`, `to_ip`, `from_ip` from (select user_id, to_ip, from_ip FROM user_access_chapter_token WHERE to_ip >= 51413955 ORDER BY to_ip ASC LIMIT 1) as `tjv` where `from_ip` <= 51413955) union (select `user_id`, `to_ip`, `from_ip` from (select user_id, to_ip, from_ip FROM user_access_disease_corporate WHERE to_ip >= 51413955 ORDER BY to_ip ASC LIMIT 1) as `tjv` where `from_ip` <= 51413955) limit 1
      12.63msalphaeurekaselec_live_10_06_2022UserAccess.php#784
      Bindings
      • 0: 51413955
      • 1: 51413955
      • 2: 51413955
      • 3: 51413955
      • 4: 51413955
      • 5: 51413955
      • 6: 51413955
      • 7: 51413955
      • 8: 51413955
      • 9: 51413955
      • 10: 51413955
      • 11: 51413955
      • 12: 51413955
      • 13: 51413955
      • 14: 51413955
      • 15: 51413955
      Backtrace
      • 14. app/Models/UserAccess/UserAccess.php:784
      • 15. middleware::check_user_access:114
      • 16. vendor/laravel/framework/src/Illuminate/Pipeline/Pipeline.php:183
      • 17. vendor/laravel/framework/src/Illuminate/Routing/Middleware/SubstituteBindings.php:50
      • 18. vendor/laravel/framework/src/Illuminate/Pipeline/Pipeline.php:183
    • SELECT at.type_name, p.copyright, p.publisher_location,m.month,y.year, a.publish_on, a.nid article_nid,a.article_id, a.pmid, a.issue_id, a.title, a.abstract,a.podcast,a.altmetric_score,a.altmetric_url,a.kudos_url, a.page_count, a.first_page, a.elocator, a.last_page, i.publication_date, a.file_name, a.file_path, a.doi, a.is_epub,a.epub_type, a.volume_id, a.is_uploaded, a.editor_choice, a.is_epub, j.image_file_name, a.article_no, a.art_type AS article_type, a.supplementary_filename,a.html_filename,a.prc_filename,a.epub_filename, a.graph_abs_lg_filename, a.graph_abs_sm_filename, a.oa_image_lg_filename, a.oa_image_sm_filename, j.journal_banner,a.animated_abstract,a.erratum_in,a.erratum_for, (CASE WHEN a.issue_id =0 THEN j.epub_price ELSE j.price END) AS sell_price, j.epub_price, j.nid AS jour_nid, j.title AS journal_title, j.issn, j.eissn,j.journal_id, j.subtitle AS jour_subtitle, v.volume_id,v.volume_name AS volume, v.year_id, i.title AS issue, i.month_id ,i.type issue_type, j.subtitle,j.formerly_title, ac.subtitle AS epub_title,a.crossmark_enabled,a.text_mining_urls,a.license_urls,a.created, a.receivedate, a.revisedate, a.acceptdate,js.js_title FROM article a LEFT JOIN article_section ac ON a.is_epub = ac.art_sec_id LEFT JOIN journal_section js ON a.js_id = js.js_id LEFT JOIN article_type at ON a.art_type = at.art_type_id LEFT JOIN issue i ON a.issue_id = i.issue_id LEFT JOIN month m ON m.id = i.month_id LEFT JOIN volume v ON v.volume_id = a.volume_id INNER JOIN year y ON y.id = v.year_id INNER JOIN journal j ON j.journal_id = a.journal_id INNER JOIN publisher p ON p.publisher_id = j.publisher_id WHERE a.article_id=120267
      640μsalphaeurekaselec_live_10_06_2022Article.php#408
      Backtrace
      • 11. app/Models/Article.php:408
      • 12. app/Http/Controllers/ArticleController.php:2515
      • 13. app/Http/Controllers/ArticleController.php:2035
      • 14. vendor/laravel/framework/src/Illuminate/Routing/Controller.php:54
      • 15. vendor/laravel/framework/src/Illuminate/Routing/ControllerDispatcher.php:43
    • select * from `journal` where `journal_id` = 1 limit 1
      710μsalphaeurekaselec_live_10_06_2022Journal.php#64
      Bindings
      • 0: 1
      Backtrace
      • 14. app/Models/Journal.php:64
      • 15. app/Http/Controllers/ArticleController.php:2516
      • 16. app/Http/Controllers/ArticleController.php:2035
      • 17. vendor/laravel/framework/src/Illuminate/Routing/Controller.php:54
      • 18. vendor/laravel/framework/src/Illuminate/Routing/ControllerDispatcher.php:43
    • select count(*) as aggregate from (select j.nid as journal_nid,j.flyer_link,j.title ,j.issn,j.eissn,j.keyword, j.journal_id as journal_id, j.subtitle, j.image_file_name,j.description,j.journal_insight_url,j.doi from `subject_journal` as `sj` inner join `journal` as `j` on `j`.`journal_id` = `sj`.`journal_id` where j.journal_status=1 and subject_id IN (SELECT subject_id FROM subject_journal WHERE journal_id=1) and sj.journal_id!=1 group by `j`.`nid`) as `aggregate_table`
      1.14msalphaeurekaselec_live_10_06_2022Subject.php#200
      Backtrace
      • 16. app/Models/Subject.php:200
      • 17. app/Http/Controllers/ArticleController.php:2517
      • 18. app/Http/Controllers/ArticleController.php:2035
      • 19. vendor/laravel/framework/src/Illuminate/Routing/Controller.php:54
      • 20. vendor/laravel/framework/src/Illuminate/Routing/ControllerDispatcher.php:43
    • select j.nid as journal_nid,j.flyer_link,j.title ,j.issn,j.eissn,j.keyword, j.journal_id as journal_id, j.subtitle, j.image_file_name,j.description,j.journal_insight_url,j.doi from `subject_journal` as `sj` inner join `journal` as `j` on `j`.`journal_id` = `sj`.`journal_id` where j.journal_status=1 and subject_id IN (SELECT subject_id FROM subject_journal WHERE journal_id=1) and sj.journal_id!=1 group by `j`.`nid` order by `j`.`journal_id` asc limit 10 offset 0
      930μsalphaeurekaselec_live_10_06_2022Subject.php#200
      Backtrace
      • 14. app/Models/Subject.php:200
      • 15. app/Http/Controllers/ArticleController.php:2517
      • 16. app/Http/Controllers/ArticleController.php:2035
      • 17. vendor/laravel/framework/src/Illuminate/Routing/Controller.php:54
      • 18. vendor/laravel/framework/src/Illuminate/Routing/ControllerDispatcher.php:43
    • select count(*) as aggregate from (select v.nid as volume_id,e.nid,e.title,v.issn,v.eissn,v.isbn,v.eisbn,e.ebook_id, v.image_file_name,v.file_path,v.flyer_link,v.ebook_volume_id, v.volume_name,v.doi,v.year_id,v.introduction from `subject_ebook` as `se` inner join `ebook` as `e` on `e`.`ebook_id` = `se`.`ebook_id` inner join `ebook_volume` as `v` on `v`.`ebook_id` = `se`.`ebook_id` inner join `year` as `y` on `y`.`id` = `v`.`year_id` where subject_id IN (SELECT subject_id FROM subject_journal WHERE journal_id=1) and v.ebook_status='1' and y.year > 2020 group by `v`.`nid`) as `aggregate_table`
      3.09msalphaeurekaselec_live_10_06_2022Subject.php#220
      Backtrace
      • 16. app/Models/Subject.php:220
      • 17. app/Http/Controllers/ArticleController.php:2518
      • 18. app/Http/Controllers/ArticleController.php:2035
      • 19. vendor/laravel/framework/src/Illuminate/Routing/Controller.php:54
      • 20. vendor/laravel/framework/src/Illuminate/Routing/ControllerDispatcher.php:43
    • select v.nid as volume_id,e.nid,e.title,v.issn,v.eissn,v.isbn,v.eisbn,e.ebook_id, v.image_file_name,v.file_path,v.flyer_link,v.ebook_volume_id, v.volume_name,v.doi,v.year_id,v.introduction from `subject_ebook` as `se` inner join `ebook` as `e` on `e`.`ebook_id` = `se`.`ebook_id` inner join `ebook_volume` as `v` on `v`.`ebook_id` = `se`.`ebook_id` inner join `year` as `y` on `y`.`id` = `v`.`year_id` where subject_id IN (SELECT subject_id FROM subject_journal WHERE journal_id=1) and v.ebook_status='1' and y.year > 2020 group by `v`.`nid` order by `v`.`ebook_volume_id` desc limit 10 offset 0
      3.24msalphaeurekaselec_live_10_06_2022Subject.php#220
      Backtrace
      • 14. app/Models/Subject.php:220
      • 15. app/Http/Controllers/ArticleController.php:2518
      • 16. app/Http/Controllers/ArticleController.php:2035
      • 17. vendor/laravel/framework/src/Illuminate/Routing/Controller.php:54
      • 18. vendor/laravel/framework/src/Illuminate/Routing/ControllerDispatcher.php:43
    • select * from `keywords` where `article_id` = '120267'
      310μsalphaeurekaselec_live_10_06_2022Keywords.php#43
      Bindings
      • 0: 120267
      Backtrace
      • 13. app/Models/Keywords.php:43
      • 14. app/Http/Controllers/ArticleController.php:2519
      • 15. app/Http/Controllers/ArticleController.php:2035
      • 16. vendor/laravel/framework/src/Illuminate/Routing/Controller.php:54
      • 17. vendor/laravel/framework/src/Illuminate/Routing/ControllerDispatcher.php:43
    • select * from `article_citation` where `article_id` = '120267'
      3.9msalphaeurekaselec_live_10_06_2022Article.php#1570
      Bindings
      • 0: 120267
      Backtrace
      • 13. app/Models/Article.php:1570
      • 14. app/Http/Controllers/ArticleController.php:2520
      • 15. app/Http/Controllers/ArticleController.php:2035
      • 16. vendor/laravel/framework/src/Illuminate/Routing/Controller.php:54
      • 17. vendor/laravel/framework/src/Illuminate/Routing/ControllerDispatcher.php:43
    • select CONCAT_WS(' ',au.first_name, ' ', ifnull(au.initials,''), ' ', au.last_name) as authors, CONCAT(au.last_name, IFNULL(CONCAT(' ', au.initials), ''), ' ', au.first_name) AS authorsRIS, CONCAT_WS(' ',au.last_name, ' ', ifnull(au.initials,''), ' ', au.first_name) as authorsCiteAs, CONCAT_WS(' ',au.first_name, IFNULL(CONCAT(' ', au.initials), ''), IFNULL(CONCAT(' ', au.last_name), '')) as authorsmodal , `au`.*, `af`.`ror_id`, `af`.`institution`, `af`.`department`, `af`.`country`, `af`.`city`, `af`.`address`, (GROUP_CONCAT(TRIM(BOTH ', ' FROM CONCAT(ifnull(concat(af.institution,','),''), ifnull(concat(af.department,','),''), ifnull(concat(af.address,','),''), ifnull(concat(af.city,','),''), ifnull(concat(af.country,','),''), ifnull(concat(af.postal_code,','),''), ifnull(concat(af.phone,','),''), ifnull(concat(af.fax,','),''))) SEPARATOR '|')) as `author_affiliation`, (GROUP_CONCAT(TRIM(BOTH ', ' FROM CONCAT(ifnull(concat(af.web_view,','),''))) SEPARATOR '|')) as `web_view` from `author` as `au` left join `author_affiliation` as `af` on `au`.`author_id` = `af`.`author_id` where `au`.`article_id` = '120267' group by `au`.`author_id` order by `au`.`article_id` asc, `au`.`sequence` asc
      1.51msalphaeurekaselec_live_10_06_2022Author.php#86
      Bindings
      • 0: 120267
      Backtrace
      • 13. app/Models/Author.php:86
      • 14. app/Http/Controllers/ArticleController.php:2533
      • 15. app/Http/Controllers/ArticleController.php:2035
      • 16. vendor/laravel/framework/src/Illuminate/Routing/Controller.php:54
      • 17. vendor/laravel/framework/src/Illuminate/Routing/ControllerDispatcher.php:43
    • select `bo`.* from `bundle_offer` as `bo` where `bo`.`bundle_status` = 'A' order by `bo`.`bundle_id` desc
      280μsalphaeurekaselec_live_10_06_2022BundleOffer.php#57
      Bindings
      • 0: A
      Backtrace
      • 13. app/Models/BundleOffer.php:57
      • 14. app/Http/Controllers/ArticleController.php:2535
      • 15. app/Http/Controllers/ArticleController.php:2035
      • 16. vendor/laravel/framework/src/Illuminate/Routing/Controller.php:54
      • 17. vendor/laravel/framework/src/Illuminate/Routing/ControllerDispatcher.php:43
    • select `subtitle` from `journal` where `continues_publication_journal` = 1
      640μsalphaeurekaselec_live_10_06_2022Article.php#1960
      Bindings
      • 0: 1
      Backtrace
      • 13. app/Models/Article.php:1960
      • 14. app/Http/Controllers/ArticleController.php:2062
      • 15. vendor/laravel/framework/src/Illuminate/Routing/Controller.php:54
      • 16. vendor/laravel/framework/src/Illuminate/Routing/ControllerDispatcher.php:43
      • 17. vendor/laravel/framework/src/Illuminate/Routing/Route.php:260
    • Select j.subtitle, v.volume_id as volume_id,v.year_id,y.year as year,v.volume_name, v.total_no_of_issues, i.issue_id as issue_id,i.title as issue, i.publication_date as issue_pub_date from journal j join volume v on j.journal_id = v.journal_id join issue i on v.volume_id = i.volume_id join article a on a.issue_id = i.issue_id join year y on v.year_id = y.id where j.journal_id = 1 and i.is_uploaded = 1 order by v.volume_name+0 desc, i.title+0 desc limit 1
      39.18msalphaeurekaselec_live_10_06_2022Issue.php#298
      Backtrace
      • 11. app/Models/Issue.php:298
      • 12. app/Http/Controllers/ArticleController.php:2068
      • 13. vendor/laravel/framework/src/Illuminate/Routing/Controller.php:54
      • 14. vendor/laravel/framework/src/Illuminate/Routing/ControllerDispatcher.php:43
      • 15. vendor/laravel/framework/src/Illuminate/Routing/Route.php:260
    • select a.nid,a.publish_on, a.pmid,a.article_id,a.doi,j.journal_id,j.subtitle,v.volume_name,a.volume_id as volume_id, a.issue_id,a.title,first_page, last_page, page_count,abstract,ifnull(is_abstract,"y"),asec.title as article_section,at.type_name as article_type_name, a.article_id as ArticleID ,is_epub,epub_price,epub_type,a.created, y.year from `article` as `a` left join `article_section` as `asec` on `asec`.`art_sec_id` = `a`.`is_epub` left join `article_type` as `at` on `at`.`art_type_id` = `a`.`art_type` left join `journal` as `j` on `j`.`journal_id` = `a`.`journal_id` inner join `volume` as `v` on `a`.`volume_id` = `v`.`volume_id` inner join `year` as `y` on `v`.`year_id` = `y`.`id` where a.article_status != "W" and a.is_epub = 1 and a.journal_id = 1 and a.is_uploaded = 1 group by `a`.`article_id` order by `a`.`publish_on` desc
      14.68msalphaeurekaselec_live_10_06_2022Article.php#528
      Backtrace
      • 13. app/Models/Article.php:528
      • 14. app/Http/Controllers/ArticleController.php:2070
      • 15. vendor/laravel/framework/src/Illuminate/Routing/Controller.php:54
      • 16. vendor/laravel/framework/src/Illuminate/Routing/ControllerDispatcher.php:43
      • 17. vendor/laravel/framework/src/Illuminate/Routing/Route.php:260
    • select a.nid,a.publish_on, a.pmid,a.article_id,a.doi,j.journal_id,j.subtitle,v.volume_name,a.volume_id as volume_id, a.issue_id,a.title,first_page, last_page, page_count,abstract,ifnull(is_abstract,"y"),asec.title as article_section,at.type_name as article_type_name, a.article_id as ArticleID ,is_epub,epub_price,epub_type,a.created, y.year from `article` as `a` left join `article_section` as `asec` on `asec`.`art_sec_id` = `a`.`is_epub` left join `article_type` as `at` on `at`.`art_type_id` = `a`.`art_type` left join `journal` as `j` on `j`.`journal_id` = `a`.`journal_id` inner join `volume` as `v` on `a`.`volume_id` = `v`.`volume_id` inner join `year` as `y` on `v`.`year_id` = `y`.`id` where a.article_status != "W" and a.is_epub = 4 and a.journal_id = 1 and a.is_uploaded = 1 group by `a`.`article_id` order by `a`.`publish_on` desc
      14.14msalphaeurekaselec_live_10_06_2022Article.php#528
      Backtrace
      • 13. app/Models/Article.php:528
      • 14. app/Http/Controllers/ArticleController.php:2071
      • 15. vendor/laravel/framework/src/Illuminate/Routing/Controller.php:54
      • 16. vendor/laravel/framework/src/Illuminate/Routing/ControllerDispatcher.php:43
      • 17. vendor/laravel/framework/src/Illuminate/Routing/Route.php:260
    • select pdf, html, epub, prc from `article_metrics` where `article_id` = 120267 limit 1
      210μsalphaeurekaselec_live_10_06_2022Article.php#744
      Bindings
      • 0: 120267
      Backtrace
      • 14. app/Models/Article.php:744
      • 15. app/Http/Controllers/ArticleController.php:2091
      • 16. vendor/laravel/framework/src/Illuminate/Routing/Controller.php:54
      • 17. vendor/laravel/framework/src/Illuminate/Routing/ControllerDispatcher.php:43
      • 18. vendor/laravel/framework/src/Illuminate/Routing/Route.php:260
    • select * from content_by_diseases where content_id = 120267 and content_type = 'article' order by status desc limit 1
      260μsalphaeurekaselec_live_10_06_2022Article.php#751
      Backtrace
      • 11. app/Models/Article.php:751
      • 12. app/Http/Controllers/ArticleController.php:2094
      • 13. vendor/laravel/framework/src/Illuminate/Routing/Controller.php:54
      • 14. vendor/laravel/framework/src/Illuminate/Routing/ControllerDispatcher.php:43
      • 15. vendor/laravel/framework/src/Illuminate/Routing/Route.php:260
    • select a.nid article_nid,a.title article_title,j.title journal_title from content_by_diseases cd inner join article a on a.article_id=cd.content_id inner join journal j on j.journal_id=a.journal_id where cd.pid = 16 and cd.sub_disease_id = 599 and content_id!=120267 and cd.content_type = 'article' order by rand() limit 20
      32.73msalphaeurekaselec_live_10_06_2022Article.php#769
      Backtrace
      • 11. app/Models/Article.php:769
      • 12. app/Http/Controllers/ArticleController.php:2098
      • 13. vendor/laravel/framework/src/Illuminate/Routing/Controller.php:54
      • 14. vendor/laravel/framework/src/Illuminate/Routing/ControllerDispatcher.php:43
      • 15. vendor/laravel/framework/src/Illuminate/Routing/Route.php:260
    • select * from `node_meta` where `nid` = 200349 limit 1
      210μsalphaeurekaselec_live_10_06_2022Meta.php#30
      Bindings
      • 0: 200349
      Backtrace
      • 14. app/Models/Meta.php:30
      • 15. app/Http/Controllers/ArticleController.php:2101
      • 16. vendor/laravel/framework/src/Illuminate/Routing/Controller.php:54
      • 17. vendor/laravel/framework/src/Illuminate/Routing/ControllerDispatcher.php:43
      • 18. vendor/laravel/framework/src/Illuminate/Routing/Route.php:260
    • select `bo`.* from `bundle_offer` as `bo` where `bo`.`bundle_status` = 'A' order by `bo`.`bundle_id` desc
      220μsalphaeurekaselec_live_10_06_2022BundleOffer.php#57
      Bindings
      • 0: A
      Backtrace
      • 13. app/Models/BundleOffer.php:57
      • 14. app/Http/Controllers/ArticleController.php:2108
      • 15. vendor/laravel/framework/src/Illuminate/Routing/Controller.php:54
      • 16. vendor/laravel/framework/src/Illuminate/Routing/ControllerDispatcher.php:43
      • 17. vendor/laravel/framework/src/Illuminate/Routing/Route.php:260
    • select * from `tbl_ht_submission` as `h` where `h`.`subtitle` = 'ACAMC' and (h.proposal_closing_date = 0 OR TO_DAYS(FROM_UNIXTIME(h.proposal_closing_date)) >= TO_DAYS(NOW())) order by `h`.`manuscript` asc
      300μsalphaeurekaselec_live_10_06_2022Article.php#2025
      Bindings
      • 0: ACAMC
      Backtrace
      • 13. app/Models/Article.php:2025
      • 14. app/Http/Controllers/ArticleController.php:2112
      • 15. vendor/laravel/framework/src/Illuminate/Routing/Controller.php:54
      • 16. vendor/laravel/framework/src/Illuminate/Routing/ControllerDispatcher.php:43
      • 17. vendor/laravel/framework/src/Illuminate/Routing/Route.php:260
    • select count(*) as total_count, content_type_access_id as access_type from journal_access where content_type_id = '120267' and content_type = 'a' and ( (from_date <= CURDATE() and to_date >= CURDATE() and perpetual= 0) or (from_date is null and to_date is null and perpetual= 1) )
      350μsalphaeurekaselec_live_10_06_2022ContentAccess.php#647
      Backtrace
      • 11. app/Models/ContentAccess.php:647
      • 12. app/Http/Controllers/ArticleController.php:2186
      • 13. vendor/laravel/framework/src/Illuminate/Routing/Controller.php:54
      • 14. vendor/laravel/framework/src/Illuminate/Routing/ControllerDispatcher.php:43
      • 15. vendor/laravel/framework/src/Illuminate/Routing/Route.php:260
    • select count(*) as total_count, content_type_access_id as access_type from journal_access where content_type_id = '11580' and content_type = 'i' and ( (from_date <= CURDATE() and to_date >= CURDATE() and perpetual= 0) or (from_date is null and to_date is null and perpetual= 1) )
      270μsalphaeurekaselec_live_10_06_2022ContentAccess.php#647
      Backtrace
      • 11. app/Models/ContentAccess.php:647
      • 12. app/Http/Controllers/ArticleController.php:2207
      • 13. vendor/laravel/framework/src/Illuminate/Routing/Controller.php:54
      • 14. vendor/laravel/framework/src/Illuminate/Routing/ControllerDispatcher.php:43
      • 15. vendor/laravel/framework/src/Illuminate/Routing/Route.php:260
    • select count(*) as total_count, content_type_access_id as access_type from journal_access where content_type_id = '3166' and content_type = 'v' and ( (from_date <= CURDATE() and to_date >= CURDATE() and perpetual= 0) or (from_date is null and to_date is null and perpetual= 1) )
      270μsalphaeurekaselec_live_10_06_2022ContentAccess.php#647
      Backtrace
      • 11. app/Models/ContentAccess.php:647
      • 12. app/Http/Controllers/ArticleController.php:2231
      • 13. vendor/laravel/framework/src/Illuminate/Routing/Controller.php:54
      • 14. vendor/laravel/framework/src/Illuminate/Routing/ControllerDispatcher.php:43
      • 15. vendor/laravel/framework/src/Illuminate/Routing/Route.php:260
    • (select j.user_access_id,j.volume_id,j.user_id,j.from_ip,j.to_ip,j.type,j.track,"Trial Access" as access_base_text, CASE j.type WHEN 111 THEN true ELSE false END as terms_popup, "S" as content_download_type, null as restricted_user_access_key, null as restricted_user_access_type, CASE j.track WHEN 0 THEN false ELSE true END as tracksAccessByVolume,"volume" as access_level,"" as issue_id,"" as article_id from `user_access_journal_volume_trail` as `j` inner join `user_access_info` as `info` on `j`.`user_access_id` = `info`.`user_access_id` where ((j.from_ip <= 51413955 and j.to_ip >=51413955 )) and ((j.from_date <= 1739834804 and j.to_date >= 1739834804 and j.perpetual= 0) or (j.from_date is null and j.to_date is null and j.perpetual= 1)) and j.volume_id = 3166) union (select j.user_access_id,j.volume_id,j.user_id,j.from_ip,j.to_ip,j.type,j.track,"Subscribed" as access_base_text, false as terms_popup, "S" as content_download_type, null as restricted_user_access_key, null as restricted_user_access_type, CASE j.track WHEN 0 THEN false ELSE true END as tracksAccessByVolume,"volume" as access_level,"" as issue_id,"" as article_id from `user_access_journal_volume_corporate` as `j` inner join `user_access_info` as `info` on `j`.`user_access_id` = `info`.`user_access_id` where ((j.from_ip <= 51413955 and j.to_ip >=51413955 )) and ((j.from_date <= 1739834804 and j.to_date >= 1739834804 and j.perpetual= 0) or (j.from_date is null and j.to_date is null and j.perpetual= 1)) and j.volume_id = 3166) union (select j.user_access_id,j.volume_id,j.user_id,j.from_ip,j.to_ip,j.type,j.track,"Token Based Access" as access_base_text, false as terms_popup, "R" as content_download_type, j.uc_id as restricted_user_access_key, "v" as restricted_user_access_type, CASE j.track WHEN 0 THEN false ELSE true END as tracksAccessByVolume,"volume" as access_level,"" as issue_id,"" as article_id from `user_access_journal_volume_token` as `j` inner join `user_access_info` as `info` on `j`.`user_access_id` = `info`.`user_access_id` where ((j.from_ip <= 51413955 and j.to_ip >=51413955 )) and ((j.from_date <= 1739834804 and j.to_date >= 1739834804 and j.perpetual= 0) or (j.from_date is null and j.to_date is null and j.perpetual= 1)) and j.volume_id = 3166)
      1.75msalphaeurekaselec_live_10_06_2022UserAccess.php#1266
      Backtrace
      • 13. app/Models/UserAccess/UserAccess.php:1266
      • 14. app/Http/Controllers/ArticleController.php:2272
      • 15. vendor/laravel/framework/src/Illuminate/Routing/Controller.php:54
      • 16. vendor/laravel/framework/src/Illuminate/Routing/ControllerDispatcher.php:43
      • 17. vendor/laravel/framework/src/Illuminate/Routing/Route.php:260
    • (select j.user_access_id,j.volume_id,j.user_id,j.from_ip,j.to_ip,j.type,j.track,"Trial Access" as access_base_text, CASE j.type WHEN 111 THEN true ELSE false END as terms_popup, "S" as content_download_type, null as restricted_user_access_key, null as restricted_user_access_type, CASE j.track WHEN 0 THEN false ELSE true END as tracksAccessByVolume,"issue" as access_level,j.issue_id,"" as article_id from `user_access_issue_trail` as `j` inner join `user_access_info` as `info` on `j`.`user_access_id` = `info`.`user_access_id` where ((j.from_ip <= 51413955 and j.to_ip >=51413955 )) and ((j.from_date <= 1739834804 and j.to_date >= 1739834804 and j.perpetual= 0) or (j.from_date is null and j.to_date is null and j.perpetual= 1)) and j.issue_id = 11580) union (select j.user_access_id,j.volume_id,j.user_id,j.from_ip,j.to_ip,j.type,j.track,"Subscribed" as access_base_text, false as terms_popup, "S" as content_download_type, null as restricted_user_access_key, null as restricted_user_access_type, CASE j.track WHEN 0 THEN false ELSE true END as tracksAccessByVolume,"issue" as access_level,j.issue_id,"" as article_id from `user_access_issue_corporate` as `j` inner join `user_access_info` as `info` on `j`.`user_access_id` = `info`.`user_access_id` where ((j.from_ip <= 51413955 and j.to_ip >=51413955 )) and ((j.from_date <= 1739834804 and j.to_date >= 1739834804 and j.perpetual= 0) or (j.from_date is null and j.to_date is null and j.perpetual= 1)) and j.issue_id = 11580) union (select j.user_access_id,j.volume_id,j.user_id,j.from_ip,j.to_ip,j.type,j.track,"Token Based Access" as access_base_text, false as terms_popup, "R" as content_download_type, j.uc_id as restricted_user_access_key, "v" as restricted_user_access_type, CASE j.track WHEN 0 THEN false ELSE true END as tracksAccessByVolume,"issue" as access_level,j.issue_id,"" as article_id from `user_access_issue_token` as `j` inner join `user_access_info` as `info` on `j`.`user_access_id` = `info`.`user_access_id` where ((j.from_ip <= 51413955 and j.to_ip >=51413955 )) and ((j.from_date <= 1739834804 and j.to_date >= 1739834804 and j.perpetual= 0) or (j.from_date is null and j.to_date is null and j.perpetual= 1)) and j.issue_id = 11580)
      540μsalphaeurekaselec_live_10_06_2022UserAccess.php#1266
      Backtrace
      • 13. app/Models/UserAccess/UserAccess.php:1266
      • 14. app/Http/Controllers/ArticleController.php:2297
      • 15. vendor/laravel/framework/src/Illuminate/Routing/Controller.php:54
      • 16. vendor/laravel/framework/src/Illuminate/Routing/ControllerDispatcher.php:43
      • 17. vendor/laravel/framework/src/Illuminate/Routing/Route.php:260
    • (select j.user_access_id,j.volume_id,j.user_id,j.from_ip,j.to_ip,j.type,j.track,"Trial Access" as access_base_text, CASE j.type WHEN 111 THEN true ELSE false END as terms_popup, "S" as content_download_type, null as restricted_user_access_key, null as restricted_user_access_type, CASE j.track WHEN 0 THEN false ELSE true END as tracksAccessByVolume,"article" as access_level, j.issue_id, j.article_id from `user_access_article_trail` as `j` inner join `user_access_info` as `info` on `j`.`user_access_id` = `info`.`user_access_id` where ((j.from_ip <= 51413955 and j.to_ip >=51413955 )) and ((j.from_date <= 1739834804 and j.to_date >= 1739834804 and j.perpetual= 0) or (j.from_date is null and j.to_date is null and j.perpetual= 1)) and j.article_id = 120267) union (select j.user_access_id,j.volume_id,j.user_id,j.from_ip,j.to_ip,j.type,j.track,"Subscribed" as access_base_text, false as terms_popup, "S" as content_download_type, null as restricted_user_access_key, null as restricted_user_access_type, CASE j.track WHEN 0 THEN false ELSE true END as tracksAccessByVolume,"article" as access_level, j.issue_id, j.article_id from `user_access_article_corporate` as `j` inner join `user_access_info` as `info` on `j`.`user_access_id` = `info`.`user_access_id` where ((j.from_ip <= 51413955 and j.to_ip >=51413955 )) and ((j.from_date <= 1739834804 and j.to_date >= 1739834804 and j.perpetual= 0) or (j.from_date is null and j.to_date is null and j.perpetual= 1)) and j.article_id = 120267) union (select j.user_access_id,j.volume_id,j.user_id,j.from_ip,j.to_ip,j.type,j.track,"Token Based Access" as access_base_text, false as terms_popup, "R" as content_download_type, j.uc_id as restricted_user_access_key, "v" as restricted_user_access_type, CASE j.track WHEN 0 THEN false ELSE true END as tracksAccessByVolume,"article" as access_level, j.issue_id, j.article_id from `user_access_article_token` as `j` inner join `user_access_info` as `info` on `j`.`user_access_id` = `info`.`user_access_id` where ((j.from_ip <= 51413955 and j.to_ip >=51413955 )) and ((j.from_date <= 1739834804 and j.to_date >= 1739834804 and j.perpetual= 0) or (j.from_date is null and j.to_date is null and j.perpetual= 1)) and j.article_id = 120267)
      560μsalphaeurekaselec_live_10_06_2022UserAccess.php#1266
      Backtrace
      • 13. app/Models/UserAccess/UserAccess.php:1266
      • 14. app/Http/Controllers/ArticleController.php:2329
      • 15. vendor/laravel/framework/src/Illuminate/Routing/Controller.php:54
      • 16. vendor/laravel/framework/src/Illuminate/Routing/ControllerDispatcher.php:43
      • 17. vendor/laravel/framework/src/Illuminate/Routing/Route.php:260
    • select * from `article` where `first_page` < '2517' and is_uploaded = 1 and issue_id = 11580 order by cast(first_page as SIGNED) desc limit 1
      530μsalphaeurekaselec_live_10_06_2022Article.php#1819
      Bindings
      • 0: 2517
      Backtrace
      • 14. app/Models/Article.php:1819
      • 15. app/Http/Controllers/ArticleController.php:2470
      • 16. vendor/laravel/framework/src/Illuminate/Routing/Controller.php:54
      • 17. vendor/laravel/framework/src/Illuminate/Routing/ControllerDispatcher.php:43
      • 18. vendor/laravel/framework/src/Illuminate/Routing/Route.php:260
    • select * from `article` where `last_page` > '2538' and is_uploaded = 1 and issue_id = 11580 order by cast(first_page as SIGNED) asc limit 1
      450μsalphaeurekaselec_live_10_06_2022Article.php#1831
      Bindings
      • 0: 2538
      Backtrace
      • 14. app/Models/Article.php:1831
      • 15. app/Http/Controllers/ArticleController.php:2472
      • 16. vendor/laravel/framework/src/Illuminate/Routing/Controller.php:54
      • 17. vendor/laravel/framework/src/Illuminate/Routing/ControllerDispatcher.php:43
      • 18. vendor/laravel/framework/src/Illuminate/Routing/Route.php:260
    • select `language_id` from `multilanguage` where `short_code` = 'en'
      170μsalphaeurekaselec_live_10_06_2022ArticleController.php#2497
      Bindings
      • 0: en
      Backtrace
      • 14. app/Http/Controllers/ArticleController.php:2497
      • 15. vendor/laravel/framework/src/Illuminate/Routing/Controller.php:54
      • 16. vendor/laravel/framework/src/Illuminate/Routing/ControllerDispatcher.php:43
      • 17. vendor/laravel/framework/src/Illuminate/Routing/Route.php:260
      • 18. vendor/laravel/framework/src/Illuminate/Routing/Route.php:206
    • select `source_lang_label`, `target_lang_label` from `multilanguage_labels` where `target_lang_id` = 1
      190μsalphaeurekaselec_live_10_06_2022MultiLanguage.php#23
      Bindings
      • 0: 1
      Backtrace
      • 13. app/Models/MultiLanguage.php:23
      • 14. app/Http/Controllers/ArticleController.php:2498
      • 15. vendor/laravel/framework/src/Illuminate/Routing/Controller.php:54
      • 16. vendor/laravel/framework/src/Illuminate/Routing/ControllerDispatcher.php:43
      • 17. vendor/laravel/framework/src/Illuminate/Routing/Route.php:260
    • select `id` from `multilanguage_article` where `article_id` = 120267 limit 1
      2.36msalphaeurekaselec_live_10_06_2022ArticleController.php#2506
      Bindings
      • 0: 120267
      Backtrace
      • 16. app/Http/Controllers/ArticleController.php:2506
      • 17. vendor/laravel/framework/src/Illuminate/Routing/Controller.php:54
      • 18. vendor/laravel/framework/src/Illuminate/Routing/ControllerDispatcher.php:43
      • 19. vendor/laravel/framework/src/Illuminate/Routing/Route.php:260
      • 20. vendor/laravel/framework/src/Illuminate/Routing/Route.php:206
    • select b.banner_link, b.banner_name, b.banner_script, b.banner_remarks, b.banner_file_name, b.banner_placement, bd.content_type, bd.content_id from `tbl_banner` as `b` inner join `tbl_banner_detail` as `bd` on `bd`.`banner_id` = `b`.`banner_id` inner join `users` as `u` on `u`.`id` = `b`.`updated_by` inner join `journal` as `j` on `j`.`journal_id` = `bd`.`content_id` where `b`.`banner_journal` = 1 and `bd`.`content_type` = 'J' and `bd`.`content_id` = 1 and `b`.`banner_from_date` <= 1739834804 and `b`.`banner_to_date` >= 1739834804 and `b`.`banner_status` = 'A' order by `b`.`banner_id` desc
      1.07msalphaeurekaselec_live_10_06_2022Banner.php#95
      Bindings
      • 0: 1
      • 1: J
      • 2: 1
      • 3: 1739834804
      • 4: 1739834804
      • 5: A
      Backtrace
      • 13. app/Models/Banner.php:95
      • 14. app/Http/helpers.php:404
      • 17. vendor/laravel/framework/src/Illuminate/Filesystem/Filesystem.php:124
      • 18. vendor/laravel/framework/src/Illuminate/View/Engines/PhpEngine.php:58
      • 19. vendor/laravel/framework/src/Illuminate/View/Engines/CompilerEngine.php:73
    • select b.banner_link, b.banner_name, b.banner_script, b.banner_remarks, b.banner_file_name, b.banner_placement, bd.content_type, bd.content_id from `tbl_banner` as `b` inner join `tbl_banner_detail` as `bd` on `bd`.`banner_id` = `b`.`banner_id` inner join `users` as `u` on `u`.`id` = `b`.`updated_by` inner join `journal` as `j` on `j`.`journal_id` = `bd`.`content_id` where `b`.`banner_journal` = 1 and `bd`.`content_type` = 'J' and `bd`.`content_id` = 1 and `b`.`banner_from_date` <= 1739834804 and `b`.`banner_to_date` >= 1739834804 and `b`.`banner_status` = 'A' order by `b`.`banner_id` desc
      1.03msalphaeurekaselec_live_10_06_2022Banner.php#95
      Bindings
      • 0: 1
      • 1: J
      • 2: 1
      • 3: 1739834804
      • 4: 1739834804
      • 5: A
      Backtrace
      • 13. app/Models/Banner.php:95
      • 14. app/Http/helpers.php:404
      • 17. vendor/laravel/framework/src/Illuminate/Filesystem/Filesystem.php:124
      • 18. vendor/laravel/framework/src/Illuminate/View/Engines/PhpEngine.php:58
      • 19. vendor/laravel/framework/src/Illuminate/View/Engines/CompilerEngine.php:73
    • select count(*) as aggregate from `uc_cart_products` where cart_id='d428aae54cfc0b61f5fc712d8be79ded'
      190μsalphaeurekaselec_live_10_06_2022Cart.php#271
      Backtrace
      • 15. app/Models/Cart.php:271
      • 16. view::layouts._header:260
      • 18. vendor/laravel/framework/src/Illuminate/Filesystem/Filesystem.php:124
      • 19. vendor/laravel/framework/src/Illuminate/View/Engines/PhpEngine.php:58
      • 20. vendor/laravel/framework/src/Illuminate/View/Engines/CompilerEngine.php:73
    App\Models\MultiLanguage
    1MultiLanguage.php#?
        _token
        TswxRGQUkSiv8EDNH6f6etbcMYVKRjjQod0BW1QL
        uc_cart_id
        d428aae54cfc0b61f5fc712d8be79ded
        _previous
        array:1 [ "url" => "http://alpha.eurekaselect.com/article/120267" ]
        _flash
        array:2 [ "old" => [] "new" => [] ]
        PHPDEBUGBAR_STACK_DATA
        []
        path_info
        /article/120267
        status_code
        200
        
        status_text
        OK
        format
        html
        content_type
        text/html; charset=UTF-8
        request_query
        []
        
        request_request
        []
        
        request_headers
        0 of 0
        array:9 [ "cookie" => array:1 [ 0 => "wayfindertarget=eyJpdiI6IlJUVit4bGxsS1gxakE3clViZ3FDTUE9PSIsInZhbHVlIjoiTnZxZEF4dXRuMW5QM25jbTl5NFRncjhtYVFUdGZGVlJZMTlhWjdyOUYzUT0iLCJtYWMiOiI4YTJjM2Y0NTJiNjI0YTQzN2Q2YjZmZmQ4Mzk2MmYxNmUwMzQ1OGRhYTRmMzg4OGQwMGNjOTVjMjdjYzAzYzRhIiwidGFnIjoiIn0%3Dwayfindertarget=eyJpdiI6IlJUVit4bGxsS1gxakE3clViZ3FDTUE9PSIsInZhbHVlIjoiTnZxZEF4dXRuMW5QM25jbTl5NFRncjhtYVFUdGZGVlJZMTlhWjdyOUYzUT0iLCJtYWMiOiI4YTJjM2Y0NTJiNjI0" ] "accept-encoding" => array:1 [ 0 => "gzip, deflate" ] "accept" => array:1 [ 0 => "text/html,application/xhtml+xml,application/xml;q=0.9,image/avif,image/webp,image/apng,*/*;q=0.8,application/signed-exchange;v=b3;q=0.7" ] "user-agent" => array:1 [ 0 => "Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)" ] "upgrade-insecure-requests" => array:1 [ 0 => "1" ] "cache-control" => array:1 [ 0 => "no-cache" ] "pragma" => array:1 [ 0 => "no-cache" ] "connection" => array:1 [ 0 => "keep-alive" ] "host" => array:1 [ 0 => "alpha.eurekaselect.com" ] ]
        request_cookies
        0 of 0
        array:1 [ "wayfindertarget" => null ]
        response_headers
        0 of 0
        array:5 [ "content-type" => array:1 [ 0 => "text/html; charset=UTF-8" ] "cache-control" => array:1 [ 0 => "no-cache, private" ] "date" => array:1 [ 0 => "Mon, 17 Feb 2025 23:26:44 GMT" ] "set-cookie" => array:2 [ 0 => "XSRF-TOKEN=eyJpdiI6Ilp0ajJza3g2Tk1RbVFUclA1KzFicUE9PSIsInZhbHVlIjoiWGltcDA5VUxPWmhPVXNBV3RQekQyYkZDcklvZ3d2YnhQRTJLTHdjNEN3d04zSml3OEpZWFp5VlR1Q1UxaU84bXlQK1ZDaUp4T1FVTm03U1YxSElqWTI2VEt6dWpqV2dSZHpSbkJPRHFneWk1b0NiNTNucTRmQXRwSzY2SURtaTAiLCJtYWMiOiIwMzExOGZlM2FjMjQzZjJjNGRlMTI4YzRmYzU5MTNmNTEyZDJiODcxMmY5MTQ3NDJkOWRmODEzMjYyNjIzNDU2IiwidGFnIjoiIn0%3D; expires=Thu, 20 Feb 2025 11:26:44 GMT; Max-Age=216000; path=/; secure; samesite=laxXSRF-TOKEN=eyJpdiI6Ilp0ajJza3g2Tk1RbVFUclA1KzFicUE9PSIsInZhbHVlIjoiWGltcDA5VUxPWmhPVXNBV3RQekQyYkZDcklvZ3d2YnhQRTJLTHdjNEN3d04zSml3OEpZWFp5VlR1Q1UxaU84bXlQK1ZDa" 1 => "alphaeurekaselectnet_session=eyJpdiI6IkNYNk40M0wwSXI4a2pUNWdHVzZBa0E9PSIsInZhbHVlIjoia1FPK3EvQU9FNUxJeVNJVWQ2bGNmR1lBZkFyTHY0TmtxNGVtOU0rL2ptM3NYYkphWTBvempoSHZyc0lya1doMTZPUGlyYlRTT0pseEZ0WS9RWis4K3YwK0c4by95UUphdko3MVA5UlB3L0dtSENSNEU3czZSM3Zmcmt4S3JFek0iLCJtYWMiOiI5YTdkYjE5NGY0YjgyZTQyZGFlZWQzZjYyNzQ5YmQwOTM3MjFlN2E3NzYyYTdjMGFmNjBhZWQ2NjRkNTRmMDBiIiwidGFnIjoiIn0%3D; path=/; secure; httponly; samesite=laxalphaeurekaselectnet_session=eyJpdiI6IkNYNk40M0wwSXI4a2pUNWdHVzZBa0E9PSIsInZhbHVlIjoia1FPK3EvQU9FNUxJeVNJVWQ2bGNmR1lBZkFyTHY0TmtxNGVtOU0rL2ptM3NYYkphWTBvempoSHZ" ] "Set-Cookie" => array:2 [ 0 => "XSRF-TOKEN=eyJpdiI6Ilp0ajJza3g2Tk1RbVFUclA1KzFicUE9PSIsInZhbHVlIjoiWGltcDA5VUxPWmhPVXNBV3RQekQyYkZDcklvZ3d2YnhQRTJLTHdjNEN3d04zSml3OEpZWFp5VlR1Q1UxaU84bXlQK1ZDaUp4T1FVTm03U1YxSElqWTI2VEt6dWpqV2dSZHpSbkJPRHFneWk1b0NiNTNucTRmQXRwSzY2SURtaTAiLCJtYWMiOiIwMzExOGZlM2FjMjQzZjJjNGRlMTI4YzRmYzU5MTNmNTEyZDJiODcxMmY5MTQ3NDJkOWRmODEzMjYyNjIzNDU2IiwidGFnIjoiIn0%3D; expires=Thu, 20-Feb-2025 11:26:44 GMT; path=/; secureXSRF-TOKEN=eyJpdiI6Ilp0ajJza3g2Tk1RbVFUclA1KzFicUE9PSIsInZhbHVlIjoiWGltcDA5VUxPWmhPVXNBV3RQekQyYkZDcklvZ3d2YnhQRTJLTHdjNEN3d04zSml3OEpZWFp5VlR1Q1UxaU84bXlQK1ZDa" 1 => "alphaeurekaselectnet_session=eyJpdiI6IkNYNk40M0wwSXI4a2pUNWdHVzZBa0E9PSIsInZhbHVlIjoia1FPK3EvQU9FNUxJeVNJVWQ2bGNmR1lBZkFyTHY0TmtxNGVtOU0rL2ptM3NYYkphWTBvempoSHZyc0lya1doMTZPUGlyYlRTT0pseEZ0WS9RWis4K3YwK0c4by95UUphdko3MVA5UlB3L0dtSENSNEU3czZSM3Zmcmt4S3JFek0iLCJtYWMiOiI5YTdkYjE5NGY0YjgyZTQyZGFlZWQzZjYyNzQ5YmQwOTM3MjFlN2E3NzYyYTdjMGFmNjBhZWQ2NjRkNTRmMDBiIiwidGFnIjoiIn0%3D; path=/; secure; httponlyalphaeurekaselectnet_session=eyJpdiI6IkNYNk40M0wwSXI4a2pUNWdHVzZBa0E9PSIsInZhbHVlIjoia1FPK3EvQU9FNUxJeVNJVWQ2bGNmR1lBZkFyTHY0TmtxNGVtOU0rL2ptM3NYYkphWTBvempoSHZ" ] ]
        session_attributes
        0 of 0
        array:5 [ "_token" => "TswxRGQUkSiv8EDNH6f6etbcMYVKRjjQod0BW1QL" "uc_cart_id" => "d428aae54cfc0b61f5fc712d8be79ded" "_previous" => array:1 [ "url" => "http://alpha.eurekaselect.com/article/120267" ] "_flash" => array:2 [ "old" => [] "new" => [] ] "PHPDEBUGBAR_STACK_DATA" => [] ]
        ClearShow all
        Date ↕MethodURLData
        #12025-02-17 23:26:44GET/article/120267414371